

COMMONWEALTH OF AUSTRALIA

IN THE MATTER OF : Australian Patent
Application 696764 (73941/94). In the name of:
Human Genome Sciences Inc.

-and-

IN THE MATTER OF: Opposition thereto by
Ludwig Institute for Cancer Research, under
Section 59 of the Patents Act.

STATUTORY DECLARATION

I, Stuart A. Aaronson of Mount Sinai Medical Center, New York, New York, United States of America, declare as follows:

1. I am currently the Director of the Derald H. Rittenberg Cancer Center for the Mount Sinai Medical Center in New York, New York. I have held this position since 1993. From 1977 to 1993, I was the Chief of the Laboratory of Cellular and Molecular Biology at the National Cancer Institute, Bethesda, Maryland. From 1970 to 1977, I was the Head of the Molecular Biology Section, from 1969 to 1970, a Senior Staff Fellow and from 1967 to 1969, a Staff Associate at the Viral Carcinogenesis Branch at the National Cancer Institute. I was awarded my M.D. in 1966 from the University of California Medical School, San Francisco.
2. Since the 1970s, my research has focused on growth factors and their role in tumorigenesis and cancer as evidenced by my curriculum vitae, which lists the publications that I have authored or co-authored. My research in the area of the molecular biology of growth factors and their receptors, including keratinocyte growth factor, fibroblast growth factor and vascular endothelial growth factor, has encompassed mammalian models of tumorigenesis,

including human tumor model systems. Now shown to me and marked "Annexure 1" is a copy of my curriculum vitae.

3. I have been asked by the Patent Attorneys representing Human Genome Sciences ("HGS") to review Australian Patent Application Au-B-696764 (73941/94) in the name of IIGS, entitled "Vascular Endothelial Growth Factor-2" ("the HGS patent specification"), which claims priority and has a virtually identical specification to U.S. application no. 08/207,550, filed March 8, 1994. I have been asked to review and comment on the experimental evidence provided in Dr. Alitalo's Statutory Declaration. I have also been asked to review and comment on the experimental evidence provided in a draft of Dr. Susan Power's Statutory Declaration, which the Patent Attorneys representing HGS have stated she will be serving in these proceedings. I have also been asked to provide my comments and opinions as to what the patent specification would provide to one of ordinary skill in the art of the molecular biology of growth factors as of the earliest filing date of the HGS patent specification, March 1994. For purposes of this analysis, I considered not only what I knew and appreciated at the relevant time, but what was expected to be known by graduate students and postdoctoral fellows who were in my laboratory at the relevant time.

Specific Comments Concerning The Patent Specification

4. I have reviewed and analyzed the polynucleotide, and amino acid sequence, identified by HGS to encode the human VEGF-2 protein, as set forth in Figure 1 of the HGS patent specification. The HGS patent specification describes, but is not limited to, the characterization of the VEGF-2 sequence and encoded protein. The HGS patent specification describes the human VEGF-2 protein as structurally related to the PDGF/VEGF family, a known family of secreted growth factors. The HGS patent specification further discloses that the VEGF-2 polynucleotide is predicted to contain an open reading frame of

approximately 1050 residues, which encodes VEGF-2. (See, the HGS patent specification at page 5, lines 25-27). The specification reports that at the amino acid level, VEGF-2 exhibits the highest homology to vascular endothelial growth factor (30% identity), followed by PDGF alpha (23%) and PDGF beta (22%). (See, the HGS patent specification at page 5, lines 28-31). The IIGS patent specification further characterizes the VEGF-2 protein as containing eight cysteines which are conserved among all known members of the PDGF/VEGF family, and in addition, also contains the fourteen amino acid signature motif, PXC VXXXRCXGCCN, found in all members of the PDGF/VEGF family. (See, the HGS patent specification at page 5, lines 31-33). The HGS patent specification speculates that the first 24 residues of the 350 amino acid sequence may encode a signal sequence. (See, the HGS patent specification at page 4, lines 29-31, and page 5, lines 26-27).

5. Based on the characterization of the VEGF-2 protein set forth in the HGS patent specification, one would recognize that the protein was a member of the PDGF/VEGF family of growth factors. The PDGF/VEGF family of growth factors, like other growth factors, must be secreted in order to exert their growth promoting or mitogenic effects. Since all previously identified members of the PDGF/VEGF family were known to be secreted, one would expect the newly identified VEGF-2 to also be secreted.
6. By March 1994 it was well known to me and, I believe to my colleagues in the angiogenic field that the PDGF/VEGF family of growth factors were expressed initially as precursor proteins which underwent proteolytic processing resulting in a mature, secreted form of the protein. Thus, I would have predicted that VEGF-2 would be expressed in a similar way. The 350 amino acid sequence set forth in Figure 1 of the HGS patent specification contains the conserved, signature motifs for an active form of a protein belonging to the PDGF/VEGF family. Thus in March 1994, I would have predicted the protein encoded by the sequence disclosed in Figure 1 of the

HGS patent specification, containing those signature motifs characteristic of the PDGF/VEGF family to be biologically active.

Specific Comments on Experimental Evidence Supplied In Dr. Alitalo's Declaration

7. Dr. Alitalo's Declaration describes experiments designed to determine whether the 350 amino acid sequence disclosed in the HGS patent specification is secreted as a mature form of the VEGF-2 protein. These experiments utilize constructs encoding amino acids 70 to 419 of the full length VEGF-2 (i.e., amino acids 1 to 350 described in the HGS patent specification) modified to contain a hemagglutinin peptide tag (HA) fused to its carboxy terminus or a vector encoding the complete 419 amino acid sequence of VEGF-C.
8. These vectors were transiently transfected into a mammalian cell line, 293T cells. The cell lysates and culture medium were assayed for the presence of newly synthesized VEGF-2/VEGF-C proteins. VEGF-2/VEGF-C were partially purified from the cell medium and cell lysates using an immunoprecipitation procedure using antibodies. The antibody used to detect VEGF-2 (70-419) was a monoclonal antibody that recognizes the hemagglutinin peptide tag. By contrast, the antibody used to immunoprecipitate VEGF-C (1-419) was a polyclonal antibody which recognizes residues 31 to 51 of the 350 amino acid VEGF-2 polypeptide. At the outset, I note that serious flaws are introduced into Dr. Alitalo's experimental design given that two different antibodies were used in the study.
9. First, Dr. Alitalo has reported the inability to isolate VEGF-C using an antibody which recognizes the C-terminal residues 372-394 or a tag attached to the C-terminus of VEGF-2 (Joukov et al., 1997, EMBO J 16: 3898, at 3900, "Joukov"). As Dr. Alitalo has reported, the amino and carboxy terminal propeptides of the precursor form of VEGF-C/VEGF-2 undergo extensive proteolytic processing, resulting in the mature form of the protein (see, Joukov

at pages 3906-7). Dr. Alitalo has also reported that the carboxy terminal propeptide "is cleaved additionally at its C-terminus," accounting for his inability to isolate VEGF-C either by using an antiserum against the C-terminal amino acid residues 372-394 or by using a tag at the C-terminus (see Joukov at page 3900, second column). If VEGF-2 is efficiently proteolytically processed to the mature form, the tag is cleaved from the carboxy terminus. The tag no longer linked to the mature form of VEGF-2 does not allow for the isolation and detection of the mature protein. Thus, the mature secreted form would not be detected using an antibody which recognizes a tag attached to the carboxy terminus, as reflected by Dr. Alitalo's own publications.

10. The HGS scientists have reported the successful isolation of a modified VEGF-2 protein containing an HA-tag at its carboxy terminus using a monoclonal antibody to HA (See, HGS Australian Patent No. 714484 and Hu J.S. et al. FASEB J. 11 (6): 498-504). However, the HGS studies were conducted in COS cells, whereas Dr. Alitalo's experiments were conducted in 293T cells (see Dr. Alitalo's Declaration at ¶ 6.2). The significance of the different cell types used is provided by Dr. Alitalo's own publications (Joukov). This publication compares the proteolytic processing of VEGF-2 expressed by a number of different cell lines, including COS cells, PC-3 cells, HT 1080 cells, and 293 ERNA cells. The results of this comparison, as reported by Dr. Alitalo was that "[t]he proteolytic processing of the VEGF-C precursor in COS cells was less efficient when compared with other cell types." (Joukov, at page 3901, second column). Thus, as the VEGF-C precursor is processed less efficiently in COS cells, the cleavage of the HA tag from the carboxy terminus should also be less efficient, which may account for HGS's ability to successfully isolate the protein from COS cells using a carboxy HA tag.
11. Second, the use of two antibodies introduces another serious flaw into the experimental design, which in the absence of the appropriate controls prevents

drawing meaningful conclusions from the data obtained. Since the antibodies recognize completely different determinants -- one within VEGF C and the other an HA-peptide tag -- each will have different affinities for the proteins they bind. Furthermore, one antibody is polyclonal and the other is monoclonal. Consequently, it is not possible to make any quantitative comparison between the results obtained for VEGF-C and VEGF-2, since the differing efficiency with which the antibodies bind their targets does not allow direct comparison of the level of proteins present in the assayed samples.

12. The aim of Dr. Alitalo's study is to determine whether VEGF-2 (HGS) is processed correctly and secreted by a mammalian cell line. However, Dr. Alitalo's experimental design allows for the detection of both the precursor and mature processed forms of VEGF-C with an anti-VEGF-C antibody; whereas the antibody used to detect VEGF-2 recognizes an HA tag fused to the C-terminus of the unprocessed form of VEGF-2 (see, Exhibit 3 of Dr. Alitalo's Declaration). As discussed in ¶ 9 above, efficient processing of the precursor protein results in extensive processing of both the amino and carboxy terminal ends thus, preventing detection of the mature protein with a carboxy terminal tag. However, the precursor form of VEGF-2 which still retains the HA tag is readily detectable (see Exhibit 3 of Dr. Alitalo's Declaration). Thus, Dr. Alitalo's experimental design allows for the detection of both unprocessed precursor form and mature VEGF-C, whereas only the unprocessed precursor form of VEGF-2 can be detected.
13. Therefore, it is not possible to draw any meaningful conclusions about the relative efficiency of secretion of VEGF-C and VEGF-2 (70 to 419) from these data -- the same antibody should have been used in both cases. Furthermore, no controls have been carried out to determine the transfection efficiency of the plasmids used -- thus preventing any valid quantitative comparisons being drawn from the data obtained.

14. Dr. Alitalo states that the expression level of VEGF-C is much higher than that of VEGF-2 (HGS), and this may be due to inefficient translation and/or that the intracellular turnover rate of VEGF2 (HGS) is much faster than that of VEGF-C (Dr. Alitalo's Declaration at ¶ 8.3). Neither of these conclusions are supported by the data set forth in Dr. Alitalo's Declaration. As discussed in ¶¶ 9 to 12 above, it is not possible to draw any conclusions from these data based on flawed quantitative comparisons. The conclusions set forth in Dr. Alitalo's Declaration are mere speculation that are unsupported by the results obtained.

Specific Comments on Experimental Evidence Supplied in Dr. Power's Declaration

15. Thus, the question of whether the 350 amino acid sequence as set forth in the HGS patent specification does indeed contain sufficient information to result in the mature processed form of VEGF-2 when secreted from a cell has, in my opinion, been addressed and affirmatively confirmed in the experiments reported in Dr. Susan Power's Statutory Declaration.
16. By March 1994, had I found that the VEGF-2 350 amino acid sequence set forth in the HGS patent specification was not secreted, in order to ensure secretion of VEGF-2, I would have engineered a heterologous signal sequence upstream and in frame with the 350 amino acid sequence, and it would have involved routine practice to do so. Indeed, this approach is specifically taught in the HGS patent specification (at page 14, lines 6-23).
17. The expectation that I and, I believe others of ordinary skill in the field would have had, that engineering a signal sequence upstream of the sequence set forth in Figure 1 of the patent specification would result in the expression and secretion of a biologically active protein as set forth in the HGS patent specification, has indeed been confirmed by the experimental evidence provided in Dr. Power's Declaration. The experiment set forth in Dr. Power's

Declaration describes the use of two constructs, the 350 amino acid sequence of VEGF-2 (as set forth in Figure 1 of the patent specification) fused in frame with a heterologous signal sequence and the 419 amino acid sequence of VEGF-2. These two constructs were used to transform a mammalian cell line. The cells were cultured under conditions to allow the cells to express the gene products encoded by the vectors. At various time points the cell lysates and culture medium were collected and each was assayed for the presence of VEGF-2. The presence of VEGF-2 was determined by a Western blot analysis using according to Dr. Power's Declaration, a polyclonal antibody to VEGF-2 that recognizes both the unprocessed precursor form as well as the processed, secreted form of VEGF-2 (See ¶ 13 of Dr. Power's Declaration).

18. Further, in my opinion, the flaws in Dr. Alitalo's experimental design which prevented any meaningful conclusions being drawn from the data presented, have been addressed in the experiments reported in Dr. Power's Declaration. First, the same antibody was used to detect the 350 amino acid sequence and the 419 amino acid sequence. Furthermore, the anti-VEGF-2 antibody used in the study is capable of detecting both the precursor form and the mature, processed form of VEGF-2. Second, the experimental protocol included comparing transfection efficiencies, and also included positive and negative controls for the expression of VEGF-2 (i.e., the expression vector encoding full-length VEGF-2 and the expression vector in the absence of any VEGF 2 sequence). In addition, the experimental protocol allowed for detection of VEGF-2 protein expression and secretion over a 72 hour time period.
19. The results of the experiments described in Dr. Power's Declaration clearly demonstrate that the 350 amino acid sequence of VEGF-2 fused in frame with a heterologous signal sequence results in the secretion of VEGF-2 from the cell (see Figure 1 of Dr. Power's Declaration). The secreted product resulting from both the 350 signal sequence construct and the 419 amino acid sequence construct, resolves as a broad band of approximately 30 kDa, and at the later

time points, e.g., 72 hours, one can also detect, in addition to this band, a minor band of approximately 21 kDa secreted by both constructs (see Figure 1 of Dr. Power's Declaration, in particular at Gel 3, lanes 22 and 24). The observation of a broad band at approximately 30 kDa and a minor band at approximately 21 kDa is consistent with Dr. Alitalo's observation that the majority of secreted VEGF-C is detected as a broad doublet band of approximately 29-31 kDa and another minor band of about 21 kDa (see, Alitalo Declaration at ¶ 7.2). Dr. Alitalo's publications also confirm that a doublet at approximately 30 kDa and another band at 21 kDa reflects a correctly processed form of VEGF-2 (see Joukov at page 3898). Thus, the results present in Dr. Power's Declaration confirm that engineering a heterologous signal sequence in frame with the coding sequence of the 350 amino acid sequence set forth in Figure 1 of the patent specification, not only results in the secretion of the protein into the culture medium, but also results in the secretion of a correctly processed mature form of VEGF-2.

20. The results of the experiments reported in Dr. Power's Declaration also demonstrate that the expression of the 350 amino acid sequence of VEGF-2 with a signal sequence contains sufficient information to allow for the correct processing of the protein to a mature biologically active protein. The expression of the 350 amino acid form of VEGF-2 results in the secretion of a proteolytically processed protein which is the same size as the secreted processed form resulting from the expression of the 419 amino acid construct. The secreted proteins which result from the expression of the 419 amino acid form of VEGF-2 and the 350 amino acid form of VEGF-2 with a signal sequence are indistinguishable in size. Both are secreted as a protein which resolves as a band at approximately 30 kDa, with another minor band detectable at approximately 21 kDa (see Figure 1 of Dr. Power's Declaration, at Gel 3, lanes 22 and 24). This is in agreement with Dr. Alitalo's observations of the mature biologically active form of VEGF-C as set forth in his declaration and publication (see ¶ 19 above). Thus, consistent with the

teaching of the HGS patent specification, the 350 amino acid sequence with a signal sequence, as set forth in the patent specification, contains sufficient information to result in the correct proteolytic processing of the VEGF-2 protein.

21. The expectation that the sequence set forth in Figure 1 of the patent specification does indeed contain the conserved motifs which would confer biological activity to the secreted VEGF-2 protein has also been confirmed by the experimental evidence provided by Dr. Power's Declaration. The results presented in Dr. Power's Declaration clearly demonstrate the 350 amino acid sequence of VEGF-2 fused in frame with a signal sequence results in the secretion of a proteolytically processed form which is resolved as a band at approximately 30 kDa and another minor band at approximately 21 kDa, the same species observed with expression of the 419 amino acid form of VEGF-2 (see Dr. Power's Declaration, Figure 1 at Gel 3, lines 22 and 24). The 30 kDa and the 21 kDa species have been consistently identified in the art as the correct processed form of VEGF-2 with biological activity. Dr. Alitalo identifies this same species as the mature biologically active form in his own declaration (see, Dr. Alitalo's Declaration at ¶ 7.2). Dr. Alitalo also identifies this same species as the mature biologically active form of VEGF-2 in his publications (see, Joukov at page 3900). Thus, the secreted VEGF-2 protein resulting from the expression of the 350 amino acid sequence set forth in the patent specification, would also be expected to have biological activity.
22. In sum, the experimental evidence provided in Dr. Power's Declaration demonstrates that the 350 amino acid sequence disclosed in the HGS patent specification fused in frame with a signal sequence results in a secreted form of VEGF-2; and that the 350 amino acid sequence contains sufficient information to be correctly processed by the cell. Furthermore, the expression of the 350 amino acid sequence with a signal sequence results in the secretion of a mature form of VEGF-2, which is indistinguishable from that observed

with expression of the 419 amino acid form of VEGF-2 as shown by both Drs. Power and Alitalo.

Conclusion

23. In my opinion, I or one skilled in the art would identify the VEGF-2 protein as a novel member of the PDGF/VEGF family of growth factors, and as such, would recognize that VEGF-2 is also a growth factor, based on the HGS patent specification in combination with the state of the art as of March 1994. I or one skilled in the art following the teaching of the HGS patent specification coupled with the state of the art, would predict that the 350 amino acid sequence with a signal sequence would result in the expression and secretion of a protein which retains VEGF-2 biological activity.
24. The experimental evidence provided in Dr. Power's Declaration confirms the teachings of the HGS patent specification, demonstrating that the 350 amino acid sequence set forth in the patent specification fused in frame to a signal sequence results in a secreted form of VEGF-2, which is correctly processed by the cell. Furthermore, these results confirm that the 350 amino acid sequence with a signal sequence contains sufficient information to be correctly processed by the cell resulting in a secreted, biologically active VEGF-2 protein.

AND I declare further that all statements made in this Declaration of my own are true in every particular, and that all statements made on information and belief are believed to be true.

Sworn by the said Stuart A. Aaronson, Stuart A. Aaronson
at New York, New York, on this 14th day of December 2000;
before me: Maryann White
Notary Public

MARYANN WHITE
NOTARY PUBLIC, State of New York
No. 4883761
Qualified in Nassau County
Certification Filed in New York County
Commission Expires January 26, 2001

CURRICULUM VITAE

Name: Stuart A. Aaronson

Date and Place of Birth: February 28, 1942, Mt. Clemens, Michigan

Citizenship: U.S.A.

Marital Status: Married, three children

Education and Training:

- 1959-1962 B.S. (Chemistry; summa cum laude), University of California, Berkeley
- 1962-1966 M.D., University of California Medical School, San Francisco
- 1965-1966 Fellowship, Dept. of Biochemistry, University of Cambridge, Cambridge, United Kingdom
- 1966-1967 Intern, Medicine, Moffitt Hospital, San Francisco

Brief Chronology of Employment:

- 1967-1969 Staff Associate, Viral Carcinogenesis Branch, National Cancer Institute, Bethesda, MD
- 1969-1970 Senior Staff Fellow, Viral Carcinogenesis Branch
- 1970-1977 Head, Molecular Biology Section, Viral Carcinogenesis Branch
- 1977-1993 Chief, Laboratory of Cellular and Molecular Biology, National Cancer Institute, Bethesda, Maryland
- 1993- Director, Ruttenberg Cancer Center, Mount Sinai Medical Center, New York, NY & Jane B. and Jack R. Aron, Professor of Neoplastic Diseases

Medical Licenses

New York
Virginia

Honors and Awards:

- 1962 Phi Beta Kappa
- 1966 Alpha Omega Alpha
- 1982 Rhoads Memorial Award
- 1982 PHS Meritorious Service Medal
- 1989 Paul Ehrlich Award
- 1989 PHS Distinguished Service Medal
- 1990 Milken Award
- 1991 Chirone Prize
- 1991 Harvey Lecture

1991 Wadsworth Memorial Foundation Award

Societies:

American Society for Microbiology
American Association for the Advancement of Science
Society for Experimental Biology and Medicine
American Association for Cancer Research, Inc.
American Society for Virology, Inc.

Memberships and Affiliations:

1975-1978 Member, Viral Cancer Program Coordinating Committee
1975-1976 Ad Hoc Member, Experimental Virology Study Section, NIH
1975-1978 Member, Viral Oncology Scientific Advisory Committee for
FCRC
1976-1980 Member, Experimental Virology Study Section, NIH
1977- Member, Editorial Board, International Journal of Cancer
1977-1986 Associate Editor, Journal of the National Cancer Institute
1980-1985 Editorial Advisory Board, Biochimica et Biophysica Acta
(BBA Reviews on Cancer)
1981- Associate Editor, Cancer Research
1983- Executive Committee, Duke Comprehensive Center, Duke
University Medical Center
1984 Mott Selection Committee, General Motors Cancer Research
Foundation
1984- Advisory Committee, Maimonides Conferences on Cancer
Research
1984-1990 Editorial Board, Virus Research
1984-1987 Scientific Advisory Committee, American Cancer Society
1985-1987 External Scientific Review Committee, Comprehensive Center,
The University of Alabama in Birmingham
1985- Editorial Advisory Board, Cancer and Metastasis Reviews
1985- Editorial Board, Cancer Reviews
1985-1989 Councillor, Society for Experimental Biology and Medicine
1985-1990 Extramural Advisory Board, Cancer Center, The University of
Arizona
1986 Program Chairman, American Association of Cancer Research
1986 Co-organizer, Princess Takamatsu Symposium
1986- Guest Editor, Japanese Journal of Cancer Research (Gann)
1986- Editorial Board, Environmental and Occupational Health Sciences
1986-1987 Member, Advisory Committee, American Type Culture Collection
1987-1989 Editorial Advisory Board, Molecular Endocrinology
1987- Editorial Board, Oncogene
1988-1989 Advisory Editorial Board, ISI Atlas of Science: Biochemistry
1988- Member, Blood Services Scientific Council, American Red
Cross
1989-1991 Editorial Board, Cancer Communications

1989-1992 Editorial Board, The New Biologist
 1989 Visiting Professor, University of Texas, San Antonio
 1990- Advisory Board, BBA Reviews on Cancer, Biochimica et
 Biophysica Acta
 1990- General Motors Visiting Professor, University of Wisconsin-
 Madison Medical School
 1990- Visiting Professor, Jonsson Comprehensive Cancer Center,
 University of California, Los Angeles
 1992- Editorial Board, Intl. Journal of Oncology
 1992- Editorial Board, Oncology Research
 1992 Scientific Advisory Board, - Georgetown Univ - Breast Ca SPORE
 1993-1995 Editorial Advisory Board, Molecular Aspects of Medicine
 1994- International Advisory Board, Tumori
 1995-1996 Vice President, Harvey Society
 1995- External Scientific Advisory Committee, UCLA Oral Cancer
 Center
 1996-1997 President, Harvey Society
 1997-1998 Counselor, Harvey Society
 1998 Member, Public Relations and Communications Committee,
 AACR
 1998 Member, The National Neurofibromatosis Foundation Research
 Advisory Board

Research Interests:

Molecular genetics of cancer; retrovirology; cellular growth regulation by growth factors and their receptors.

Patents:

More than 50 patent applications issued or pending.

Social Security Number:

571-58-5069

Present Address:

40 East 94th Street, Apt. 23B
 New York, NY 10128

BIBLIOGRAPHY

Stuart A. Aaronson

1. Aaronson, S. A., Natori, Y., and Tarver, H.: Effect of estrogen on uterine ATP levels. Proc. Soc. Exp. Biol. Med. 120: 9-13, 1965.
2. Aaronson, S. A., Korner, A., and Munro, A. J.: Inhibition of soluble ribonucleic acid of stimulatory effect of liver template ribonucleic acid. Biochem. J. 101: 448-453, 1966.
3. Aaronson, S. A. and Todaro, G. J.: SV40 T antigen induction and transformation in human fibroblast cells. Virology 36: 254-261, 1968.
4. Aaronson, S. A. and Todaro, G. J.: Development of 3T3-like lines from BALB/c mouse embryo cultures: transformation susceptibility to SV40. J. Cell Physiol. 72: 141-148, 1968.
5. Todaro, G. J. and Aaronson, S. A.: Human cell strains susceptible to focus formation by human adenovirus type 12. Proc. Natl. Acad. Sci. USA 61: 1272-1278, 1968.
6. Aaronson, S. A. and Todaro, G. J.: Basis for the acquisition of malignant potential by mouse cells cultivated *in vitro*. Science 162: 1024-1026, 1968.
7. Todaro, G. J. and Aaronson, S. A.: Properties of clonal lines of murine sarcoma virus transformed BALB/3T3 cells. Virology 38: 174-179, 1969.
8. Aaronson, S. A. and Todaro, G. J.: Human diploid cell transformation by DNA extracted from the tumor virus, SV40. Science 166: 390-391, 1969.
9. Aaronson, S. A., Hartley, J. A., and Todaro, G. J.: Mouse leukemia virus "spontaneous" release by mouse embryo cells after long-term *in vitro* cultivation. Proc. Natl. Acad. Sci. USA 65: 87-94, 1969.
10. Jainchill, J. L., Aaronson, S. A., and Todaro, G. J.: Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells. J. Virol. 4: 549-553, 1969.
11. Pollock, E. J., Aaronson, S. A., and Todaro, G. J.: X-irradiation of BALB/3T3: sarcoma forming ability and virus induction. Int. J. Radiat. Biol. 17: 97-100, 1970.

12. Aaronson, S. A. and Todaro, G. J.: Transformation and virus growth by murine sarcoma viruses and human cells. Nature 225: 458-459, 1970.
13. Aaronson, S. A. and Todaro, G. J.: Infectious SV40 and SV40 DNA: rapid fluorescent focus assay. Proc. Soc. Exp. Biol. Med. 134: 103-106, 1970.
14. Todaro, G. J., Zeve, V., and Aaronson, S. A.: Virus in cell cultures derived from human tumor patients. Nature 226: 1047-1048, 1970.
15. Aaronson, S. A., Todaro, G. J., and Freeman, A. E.: Human sarcoma cells in culture: identification by colony-forming ability on monolayers of normal cells. Exp. Cell Res. 61: 1-5, 1970.
16. Aaronson, S. A. and Rowe, W. P.: Nonproducer clones of murine sarcoma virus transformed BALB/3T3 cells. Virology 42: 9-19, 1970.
17. Aaronson, S. A., Jainchill, J. L., and Todaro, G. J.: Murine sarcoma virus transformation of BALB/3T3 cells: lack of dependence on murine leukemia virus. Proc. Natl. Acad. Sci. USA 66: 1236-1243, 1970.
18. Aaronson, S. A.: Effect of ultraviolet irradiation on the survival of SV40 functions in human and mouse cells. J. Virol. 6: 393-399, 1970.
19. Aaronson, S. A. and Lytle, C.: Decreased host cell reactivation of irradiated SV40 virus in Xeroderma pigmentosum. Nature 228: 359-361, 1970.
20. Scolnick, E. M., Aaronson, S. A., and Todaro, G. J.: DNA synthesis by RNA tumor viruses. Proc. Natl. Acad. Sci. USA 67: 1034-1041, 1970.
21. Aaronson, S. A. and Martin, M. A.: Transformation of human cells with different forms of SV40 DNA. Virology 42: 848-856, 1970.
22. Aaronson, S. A.: Susceptibility of human cell strains to transformation by SV40 and SV40 DNA. J. Virol. 6: 470-475, 1970.
23. Kelloff, G., Aaronson, S. A., and Gilden, R.V.: Inactivation of murine sarcoma and leukemia viruses by ultraviolet irradiation. Virology 42: 1133-1135, 1970.
24. Gerwin, B. I., Todaro, G. J., Zeve, V., Scolnick, E. M., and Aaronson, S. A.: Separation of RNA-dependent DNA polymerase activity from the murine leukemia virion. Nature 228: 435-438, 1970.

25. Scolnick, E. M., Rands, E., Aaronson, S. A., and Todaro, G. J.: RNA-dependent DNA polymerase activity in five RNA viruses: divalent cation requirements. Proc. Natl. Acad. Sci. USA 67: 1789-1796, 1970.
26. Aaronson, S. A.: Human cell transformation by SV40 and SV40 DNA. In Lapedes, D. N. (Ed): McGraw-Hill Yearbook of Science and Technology. New York, McGraw-Hill, Inc., 1971, pp. 421-423.
27. Aaronson, S. A., Todaro, G. J., and Huebner, R. J.: Transformation by murine sarcoma virus. In Silvestri, L. G. (Ed.): The Biology of Oncogenic Viruses. Amsterdam, North Holland Publishing Co., 1971, pp. 138-144.
28. Todaro, G. J., Aaronson, S. A., Scolnick, E. M., and Parks, W. P.: RNA-dependent DNA polymerase in viruses and in cells. In Silvestri, L. G. (Ed.): The Biology of Oncogenic Viruses. Amsterdam, North Holland Publishing Co., 1971, pp. 206-209.
29. Stone, L. B., Scolnick, E. M., Takemoto, K. K., and Aaronson, S. A.: Visna virus: a slow virus with an RNA dependent DNA polymerase. Nature 229: 257-258, 1971.
30. Aaronson, S. A.: Isolation of a rat-tropic helper virus from M-MSV-O stocks. Virology 44: 29-36, 1971.
31. Todaro, G. J., Aaronson, S. A., and Rands, E.: Rapid detection of mycoplasma infected cell cultures. Exp. Cell Res. 65: 256-258, 1971.
32. Todaro, G. J., Zeve, V., and Aaronson, S. A.: Cell culture techniques in the search for cancer viruses in man. In Vitro 6: 355-361, 1971.
33. Parks, W. P., Scolnick, E. M., Todaro, G. J., and Aaronson, S. A.: RNA-dependent DNA polymerase in primate syncytium-forming ("foamy") viruses. Nature 229: 258-260, 1971.
34. Scolnick, E. M., Aaronson, S. A., Todaro, G. J., and Parks, W. P.: RNA-dependent DNA polymerase activity in mammalian cells. Nature 235: 318-321, 1971.
35. Worthington, M. and Aaronson, S. A.: Interferon system in cells from human tumors and from persons predisposed to cancer. Infect. Immun. 3: 424-428, 1971.
36. Aaronson, S. A., Parks, W. P., Scolnick, E. M., and Todaro, G. J.: Antibody to the RNA-dependent DNA polymerase of mammalian C-type RNA tumor viruses. Proc. Natl. Acad. Sci. USA 68: 920-924, 1971.

37. Aaronson, S. A.: Common genetic alterations of RNA tumor viruses grown in human cells. Nature 230: 445-447, 1971.
38. Aaronson, S. A. and Weaver, C. A.: Characterization of murine sarcoma virus (Kirsten) transformation of mouse and human cells. J. Gen. Virol. 13: 245-252, 1971.
39. Gelb, L. D., Aaronson, S. A., and Martin, M. A.: Heterogeneity of murine leukemia virus in *in vitro* DNA: detection of viral DNA in mammalian cells. Science 172: 1353-1355, 1971.
40. Stephenson, J. R. and Aaronson, S. A.: Murine sarcoma and leukemia viruses: genetic differences determined by RNA-DNA hybridization. Virology 46: 480-484, 1971.
41. Ross, J., Scolnick, E. M., Todaro, G. J., and Aaronson, S. A.: Separation of murine cellular and murine leukemia virus DNA polymerases. Nature 231: 153-167, 1971.
42. Aaronson, S. A., Todaro, G. J., and Scolnick, E. M.: Induction of murine C-type viruses from clonal lines of virus-free BALB/3T3 cells. Science 174: 157-159, 1971.
43. Aaronson, S. A.: Chemical induction of focus-forming virus from nonproducer cells transformed by murine sarcoma virus. Proc. Natl. Acad. Sci. USA 68: 3069-3072, 1971.
44. Parks, W. P., Scolnick, E. M., Ross, J., Todaro, G. J., and Aaronson, S. A.: Immunologic relationships of reverse transcriptases from ribonucleic acid tumor viruses. J. Virol. 9: 110-115, 1972.
45. Stephenson, J. R. and Aaronson, S. A.: Antigenic properties of murine sarcoma virus transformed BALB/3T3 nonproducer cells. J. Exp. Med. 135: 503-513, 1972.
46. Scolnick, E. M., Parks, W. P., Todaro, G. J., and Aaronson, S. A.: Immunological characterization of primate C-type virus reverse transcriptases. Nature New Biol. 235: 35-40, 1972.
47. Lytle, C. D., Aaronson, S. A., and Harvey, E.: Host cell reactivation in mammalian cells. II. Survival of herpes simplex virus and vaccinia virus in normal human and Xeroderma pigmentosum cells. Int. J. Radiat. Biol. 22 159-165, 1972.

48. Stephenson, J. R., Reynolds, R. K., and Aaronson, S. A.: Isolation of temperature-sensitive mutants of murine leukemia virus. Virology 48: 749-756, 1972.
49. Stephenson, J. R., Scolnick, E. M., and Aaronson, S. A.: Genetic stability of the sarcoma viruses in murine and avian sarcoma virus transformed nonproducer cells. Int. J. Cancer 9: 577-583, 1972.
50. Aaronson, S. A., Bassin, R. H., and Weaver, C. A.: Comparison of murine sarcoma viruses in nonproducer and S⁺L⁻ transformed cells. J. Virol. 9: 701-704, 1972.
51. Kersey, J. H., Gatti, R. A., Good, R. A., Aaronson, S. A., and Todaro, G. J.: Susceptibility of cells from patients with primary immunodeficiency diseases to transformation by simian virus 40. Proc. Natl. Acad. Sci. USA 69: 980-982, 1972.
52. Stephenson, J. R. and Aaronson, S. A.: Genetic factors influencing C-type RNA virus induction. J. Exp. Med. 136: 175-184, 1972.
53. Aaronson, S. A.: Immunologic detection of C-type RNA viral reverse transcriptases. Natl. Cancer Inst. Monogr. 35: 83-87, 1972.
54. Stephenson, J. R. and Aaronson, S. A.: A genetic locus for inducibility of C-type virus in BALB/c cells: the effect of a nonlinked regulatory gene on detection of virus after chemical activation. Proc. Natl. Acad. Sci. USA 69: 2798-2801, 1972.
55. Aaronson, S. A. and Stephenson, J. R.: Genetic factors involved in C-type RNA virus expression. In Day, S. B. and Good, R. A. (Eds.): Membranes and Viruses in Immuno-pathology. New York, Academic Press, 1972, pp.355-366
56. Scolnick, E. M., Stephenson, J. R., and Aaronson, S. A.: Isolation of temperature-sensitive mutants of murine sarcoma virus. J. Virol. 10: 653-657, 1972.
57. Todaro, G. J., Aaronson, S. A., Scolnick, E. M., Ross, J., and Parks, W. P.: Reverse transcriptase of RNA tumor viruses: immunological relationships. In Dutcher, R. M., and Chieco-Bianchi, L. (Eds.): Unifying Concepts of Leukemia. Basel, Karger, 1973, pp. 269-271.
58. Aoki, T., Stephenson, J. R., and Aaronson, S. A.: Demonstration of a cell-surface antigen associated with murine sarcoma virus by immunoelectron microscopy. Proc. Natl. Acad. Sci. USA 70: 742-746, 1973.
59. Stephenson, J. R., Reynolds, R. K., and Aaronson, S. A.: Characterization of morphologic revertants of murine and avian sarcoma virus-transformed cells. J. Virol. 11: 218-222, 1973.

60. Aaronson, S. A. and Stephenson, J. R.: Endogenous RNA C-type viruses of mammalian cells. In Silvestri, L.G. (Ed.): Possible Episomes in Eukaryotes. Amsterdam, North Holland Publishing Co., 1973, pp. 42-49.
61. Aaronson, S. A.: Biologic characterization of mammalian cells transformed by a primate sarcoma virus. Virology 52: 562-567, 1973.
62. Kersey, J. H., Yunis, E. J., Todaro, G. J., and Aaronson, S. A.: HL-A antigens of human tumor derived cell lines and viral-transformed fibroblasts in culture. Proc. Soc. Exp. Biol. Med. 143: 453-456, 1973.
63. Stephenson, J. R. and Aaronson, S. A.: Segregation of genetic loci for C-type virus activation in high and low leukemia incidence strains of mice. Science 180: 865-866, 1973.
64. Stephenson, J. R. and Aaronson, S. A.: Characterization of temperature sensitive mutants of murine leukemia virus. Virology 54: 53-59, 1973.
65. Aaronson, S. A. and Stephenson, J. R.: Independent segregation of loci for activation of biologically distinguishable RNA C-type viruses in mouse cells. Proc. Natl. Acad. Sci. USA 70: 2055-2058, 1973.
66. Tronick, S. R., Stephenson, J. R., and Aaronson, S. A.: Immunological characterization of a low molecular weight polypeptide of murine leukemia virus. Virology 54: 199-206, 1973.
67. Gelb, L. D., Milstien, J. B., Martin, M. A., and Aaronson, S. A.: Characterization of murine leukemia virus-specific DNA present in normal mouse cells. Nature New Biol. 244: 76-79, 1973.
68. Stephenson, J. R., Wilsnack, R. E., and Aaronson, S. A.: Radioimmunoassay for avian C-type virus group specific antigen: detection in normal and virus transformed cells. J. Virol. 11: 893-899, 1973.
69. Stephenson, J. R. and Aaronson, S. A.: Expression of endogenous RNA C-type virus group specific antigens in mammalian cells. J. Virol. 12: 564-569, 1973.
70. Giard, D. J., Aaronson, S. A., Todaro, G. J., Arnstein, P., Kersey, J. H., Dosik, H., and Parks, W. P.: *In vitro* cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J. Natl. Cancer Inst. 51: 1417-1423, 1973.

71. Greenberger, J. S. and Aaronson, S. A.: *In vivo* inoculation of RNA C-type viruses inducing regression of experimental solid tumors. J. Natl. Cancer Inst. 51: 1935-1938, 1973.
72. Fishman, P. H., Brady, R. O., Bradley, R. M., Aaronson, S. A., and Todaro, G. J.: Absence of a specific gaglioside galactosyl-transferase in murine sarcoma virus-transformed mouse cells. Proc. Natl. Acad. Sci. USA 71: 298-301, 1974.
73. Stephenson, J. R., Greenberger, J. S., and Aaronson, S. A.: Oncogenicity of an endogenous C-type virus chemically activated from mouse cells in culture. J. Virol. 13: 237-240, 1974.
74. Stephenson, J. R., Tronick, S. R., and Aaronson, S. A.: Analysis of type-specific antigenic determinants of two structural polypeptides of mouse RNA C-type viruses. Virology 58: 1-8, 1974.
75. Greenberger, J. S. and Aaronson, S. A.: Morphologic revertants of murine sarcoma virus transformed nonproducer BALB/3T3: selective techniques for isolation and biologic properties *in vitro* and *in vivo*. Virology 57: 339-346, 1974.
76. Aaronson, S. A. and Dunn, C. Y.: Endogenous C-type viruses of BALB/C cells: frequencies of spontaneous and chemical induction. J. Virol. 13: 181-185, 1974.
77. Aaronson, S. A. and Dunn, C. Y.: High frequency C-type virus induction by inhibitors of protein synthesis. Science 183: 422-423, 1974.
78. Stephenson, J. R. and Aaronson, S. A.: Temperature-sensitive mutants of murine leukemia virus. III. Mutants defective in helper functions for sarcoma virus fixation. Virology 58: 294-297, 1974.
79. Tronick, S. R., Stephenson, J. R., and Aaronson, S. A.: Comparative immunological studies of primate RNA C-type viruses. Radioimmunoassay for a low molecular weight polypeptide of woolly monkey leukemia virus. Virology 57: 347-356, 1974.
80. Stephenson, J. R., Tronick, S. R., Reynolds, R. K., and Aaronson, S. A.: Isolation and characterization of C-type viral gene products of virus-negative mouse cells. J. Exp. Med. 139: 427-438, 1974.
81. Aaronson, S. A. and Stephenson, J. R.: Widespread natural occurrence of high-titered neutralizing antibodies to a specific class of endogenous mouse type C virus. Proc. Natl. Acad. Sci. USA 71: 1957-1961, 1974.

82. Stephenson, J. R., Aaronson, S. A., Arnstein, P., Huebner, R. J., and Tronick, S. R.: Demonstration of two immunologically distinct xenotropic RNA type C viruses of mouse cells. Virology 61: 56-63, 1974.
83. Aaronson, S. A., Stephenson, J. R., and Greenberger, J. S.: Cellular replication and the persistence of inducible RNA type C viruses. J. Virol. 13: 1404-1407, 1974.
84. Stephenson, J. R., Crow, J. D., and Aaronson, S. A.: Differential activation of biologically distinguishable endogenous mouse type C RNA viruses: interactions with host cell regulatory factors. Virology 61: 411-419, 1974.
85. Tronick, S. R., Stephenson, J. R., and Aaronson, S. A.: Immunological properties of two polypeptides of Mason-Pfizer monkey virus. J. Virol. 14: 125-132, 1974.
86. Stephenson, J. R., Anderson, G. R., Tronick, S. R., and Aaronson, S. A.: Evidence for genetic recombination between endogenous and exogenous mouse RNA type C viruses. Cell 2: 87-94, 1974.
87. Greenberger, J. S., Stephenson, J. R., Aoki, T., and Aaronson, S. A.: Cell surface antigens of murine sarcoma virus transformed nonproducer cells: further evidence for lack of transplantation immunity. Int. J. Cancer 14: 145-152, 1974.
88. Greenberger, J. S., Anderson, G. R., and Aaronson, S. A.: Transformation-defective virus mutants in a class of morphologic revertants of sarcoma virus-transformed nonproducer cells. Cell 2: 279-286, 1974.
89. Aaronson, S. A. and Stephenson, J. R.: Cellular regulation of biologically distinguishable endogenous mouse type C viruses. In Robinson, W. S. and Fox, C. F. (Eds.): Mechanisms of Virus Disease. Menlo Park, Calif., W.A. Benjamin, Inc., 1974, pp. 49-67.
90. Lee, J. C., Hanna, M. G., Jr., Ihle, J. N., and Aaronson, S. A.: Autogenous immunity to endogenous RNA tumor virus: differential reactivities of immunoglobins M and G to virus envelope antigens. J. Virol. 14: 773-781, 1974.
91. Stephenson, J. R., Tronick, S. R., and Aaronson, S. A.: Temperature-sensitive mutants of murine leukemia virus. IV. Further physiologic characterization and evidence for genetic recombination. J. Virol. 14: 918-923, 1974.
92. Aaronson, S. A., Anderson, G. R., Dunn, C. Y., and Robbins, K. C.: Induction of type C RNA virus by cycloheximide: increased expression of virus specific RNA. Proc. Natl. Acad. Sci. USA 71: 3941-3945, 1974.

93. Aoki, T., Stephenson, J. R., Aaronson, S. A., and Hsu, K. C.: Surface antigens of mammalian sarcoma virus-transformed nonproducer cells. Proc. Natl. Acad. Sci. USA 71: 3445-3449, 1974.
94. Stephenson, J. R., Tronick, S. R., and Aaronson, S. A.: Isolation from BALB/C mouse cells of a structural polypeptide of a third endogenous type C virus class. Cell 3: 347-353, 1974.
95. Stephenson, J. R. and Aaronson, S. A.: Demonstration of a genetic factor influencing spontaneous release of a xenotropic virus of mouse cells. Proc. Natl. Acad. Sci. USA 71: 4925-4929, 1974.
96. Aaronson, S. A. and Stephenson, J. R.: Differential cellular regulation of three distinct classes of type C RNA viruses endogenous to mouse cells. Cold Spring Harbor Symp. Quant. Biol. 39: 1129-1137, 1975.
97. Stephenson, J. R. and Aaronson, S. A.: Genetics of endogenous mouse C-type viruses. In Ito, Y. and Dutcher, R. M. (Eds.): Comparative Leukemia Research, Leukemogenesis, 1973. Tokyo, Univ. Tokyo Press, 1975, pp. 657-658.
98. Greenberger, J. S. and Aaronson, S. A.: Cycloheximide induction of xenotropic type C virus from synchronized mouse cells: metabolic requirements for virus activation. J. Virol. 15: 64-70, 1975.
99. Greenberger, J. S., Stephenson, J. R., Moloney, W. C., and Aaronson, S. A.: Different hematologic diseases induced by type C viruses chemically activated from embryo cells of different mouse strains. Cancer Res. 35: 245-252, 1975.
100. Aaronson, S. A. and Schlom, J.: The search for RNA tumor viruses in human cancer. In Airel, I. M. (Ed.): Progress in Clinical Cancer. New York, Grune and Stratton, 1975, pp. 51-63.
101. Tronick, S. R., Stephenson, J. R., Aaronson, S. A., and Kawakami, T. G.: Antigenic characterization of type C RNA virus isolates of gibbon apes. J. Virol. 15: 115-120, 1975.
102. Greenberger, J. S., Rosenthal, D. S., Aaronson, S. A., and Moloney, W. C.: Acute myelogenous leukemia of the Wistar-Furth rat: establishment of a continuous tissue culture line producing lysozyme *in vitro* and *in vivo*. Blood 46: 27-38, 1975.
103. Greenberger, J. S., Phillips, S. M., Stephenson, J. R., and Aaronson, S. A.: Induction of mouse type C RNA virus by lipopolysaccharide and concanavalin A. J. Immunol. 115: 317-320, 1975.

104. Stephenson, J. R., Reynolds, R. K., Tronick, S. R., and Aaronson, S. A.: Distribution of three classes of endogenous type C RNA viruses among inbred strains of mice. Virology 67: 404-414, 1975.
105. Dunn, C. Y., Aaronson, S. A., and Stephenson, J. R.: Interactions of chemical inducers and steroid enhancers of endogenous mouse type C RNA viruses. Virology 66: 579-588, 1975.
106. Greenberger, J. S., Aaronson, S. A., Rosenthal, D. S., and Moloney, W. C.: Continuous production of peroxidase, esterase, alkaline phosphatase and lysozyme by clones of promyelocytes. Nature 257: 143-144, 1975.
107. Greenberger, J. S., Stephenson, J. R., and Aaronson, S. A.: Temperature-sensitive mutants of murine leukemia virus. V. Impaired leukemogenic activity *in vivo*. Int. J. Cancer 15: 1009-1015, 1975.
108. Stephenson, J. R., Smith, E. J., Crittenden, L. B., and Aaronson, S. A.: Analysis of antigenic determinants of structural polypeptides of avian type C RNA tumor viruses. J. Virol. 16: 27-33, 1975.
109. Hino, S., Stephenson, J. R., and Aaronson, S. A.: Antigenic determinants of the 70,000 molecular weight glycoprotein of woolly monkey type C RNA virus. J. Immunol. 115: 922-927, 1975.
110. Tronick, S. R., Stephenson, J. R., Verma, I. M., and Aaronson, S. A.: A thermolabile reverse transcriptase of a mammalian leukemia virus mutant temperature-sensitive in its replication and sarcoma virus helper functions. J. Virol. 16: 1476-1482, 1975.
111. Tronick, S. R., Stephenson, J. R., Verma, I. M., and Aaronson, S. A.: A thermolabile reverse transcriptase from a temperature-sensitive mutant of murine leukemia virus. In Gouliau, M. and Hanawalt, P. (Eds.): DNA Synthesis and its Regulation. Menlo Park, W. A. Benjamin, Inc.,
112. Stephenson, J. R., Tronick, S. R., and Aaronson, S. A.: Murine leukemia virus mutants with temperature-sensitive defects in precursor polypeptide cleavage. Cell 6: 543-548, 1975.
113. Aaronson, S. A., Stephenson, J. R., Hino, S., and Tronick, S. R.: Differential expression of helper viral structural polypeptides in cells transformed by clonal isolates of woolly monkey sarcoma virus. J. Virol. 16: 1117-1123, 1975.

114. Aaronson, S. A. and Stephenson, J. R.: Viruses and the etiology of cancer. In Drew, W. L. (Ed.): Clinical Concepts in Virology. Philadelphia, F. A. Davis, 1976, pp. 251-292.
115. Gonda, M. A., Aaronson, S. A., Ellmore, N., Zeve, V. H., and Hagashima, K.: Ultrastructural studies of surface features of human, normal and tumor cells in tissue culture by scanning and transmission electron microscopy. J. Natl. Cancer Inst. 56: 245-263, 1976.
116. Stephenson, J. R., Reynolds, R. K., and Aaronson, S. A.: Comparisons of the immunological properties of two structural polypeptides of type C RNA viruses endogenous to Old World monkeys. J. Virol. 17: 374-384, 1976.
117. Kelloff, G. J., Peters, R. L., Donahoe, R. M., Stephenson, J. R., and Aaronson, S. A.: Natural occurrence of tumors in mouse strains with different xenotropic and ecotropic endogenous viruses. J. Natl. Cancer Inst. 57: 85-89, 1976.
118. Phillips, S. M., Stephenson, J. R., Greenberger, J. S., Lane, P. E., and Aaronson, S. A.: Release of xenotropic type C RNA virus in response to lipopolysaccharide: activity of lipid-A portion upon B lymphocytes. J. Immunol. 116: 1123-1128, 1976.
119. Fishman, P. H., Brady, R., and Aaronson, S. A.: A comparison of membrane glycoconjugates from mouse cells transformed by murine and primate RNA sarcoma viruses. Biochemistry 15: 201-208, 1976.
120. Smith, E. J., Stephenson, J. R., Crittenden, L. B., and Aaronson, S. A.: Avian leukosis-sarcoma virus gene expression: noncoordinate control of group specific antigens in virus-negative avian cells. Virology 70: 493-501, 1976.
121. Stephenson, J. R. and Aaronson, S. A.: Induction of an endogenous B-tropic type C RNA virus from SWR/J mouse embryo cells in tissue culture. Virology 70: 352-359, 1976.
122. Aaronson, S. A., Stephenson, J. R., Tronick, S. R., and Hino, S.: Immunological analysis of structural polypeptides of woolly monkey-gibbon ape type C viruses: woolly monkey sarcoma virus. In Clemmesen, J. and Yohn, D. S. (Eds.): Comparative Leukemia Research, 1975. Basel, Karger, 1976, pp. 102-109.
123. Okabe, H., Gilden, R. V., Hatanaka, M., Stephenson, J. R., Gallagher, R. E., Gallo, R. C., and Aaronson, S. A.: Immunologic and biochemical characterization of type C viruses isolated from cultured human AML cells. Nature 260: 264-266, 1976.

124. Hampar, B., Aaronson, S. A., Derbe, J. G., Chakrabarty, M., Showalter, S. A., and Dunn, C. Y.: Activation of an endogenous mouse type C virus by ultraviolet-irradiated herpes simplex virus types 1 and 2. Proc. Natl. Acad. Sci. USA 73: 646-650, 1976.
125. Greenberger, J. S., Bensinger, W. I., and Aaronson, S. A.: Selective techniques for the isolation of morphologic revertants of sarcoma virus transformed cells. In Prescott, D. (Ed.): Methods in Cell Biology. New York, Academic Press, 1976, pp. 237-248.
126. Aaronson, S. A., Stephenson, J. R., Hino, S., and Cabradilla, C.: Endogenous type C RNA viruses of mouse cells: a model for the study of gene regulation in eukaryotes. In Criss, W. E., Ono, T., and Sabine, J. R. (Eds.): Control Mechanisms in Cancer. New York, Raven Press, 1976, pp. 279-294.
127. Stephenson, J. R. and Aaronson, S. A.: Search for antigens and antibodies crossreactive with type C viruses of the woolly monkey and gibbon ape in animal models and in humans. Proc. Natl. Acad. Sci. USA 73: 1725-1729, 1976.
128. Aaronson, S. A. and Stephenson, J. R.: Endogenous type C RNA viruses of mammalian cells. Biochim. Biophys. Acta 458: 323-354, 1976.
129. Stephenson, J. R., Cabradilla, C. D., and Aaronson, S. A.: Genetic factors influencing endogenous type C RNA viruses of mouse cells: control of viral polypeptide expression in the C57BL/10 strain. Intervirology 6: 258-269, 1976.
130. Hino, S., Stephenson, J. R., and Aaronson, S. A.: Radio-immunoassays for the 70,000 molecular weight glycoprotein of endogenous mouse type C viruses: viral antigen expression in normal mouse tissues. J. Virol. 18: 933-941, 1976.
131. Barbacid, M., Stephenson, J. R., and Aaronson, S. A.: Structural polypeptides of mammalian type C RNA viruses: isolation and immunologic characterization of a low molecular weight polypeptide, p10. J. Biol. Chem. 251: 4859-4866, 1976.
132. Stephenson, J. R., Hino, S., Garrett, E. W., and Aaronson, S. A.: Immunological cross-reactivity of Mason-Pfizer monkey virus with type C RNA viruses endogenous in primates. Nature 261: 609-611, 1976.
133. Barbacid, M., Stephenson, J. R., and Aaronson, S. A.: The gag gene of mammalian type C RNA tumor viruses. Nature 262: 554-559, 1976.
134. Barbacid, M., Stephenson, J. R., and Aaronson, S. A.: Endogenous type C RNA virus of *Odocoileus heminus*, a mammalian species of New World origin. Cell 9: 489-494, 1976.

135. Stephenson, J. R., Hino, S., Peters, R. L., Donahoe, R. M., Long, L. K., Aaronson, S. A., and Kelloff, G. J.: Natural immunity to structural polypeptides of endogenous type C RNA viruses. J. Virol. 19: 890-898, 1976.
136. Cabradilla, C. D., Robbins, K. C., and Aaronson, S. A.: Induction of mouse type C virus by translational inhibitors: evidence for transcriptional derepression of a specific class of endogenous virus. Proc. Natl. Acad. Sci. USA 73: 4541-4545, 1976.
137. Devare, S. G., Stephenson, J. R., Chander, S., Sarma, P. S., and Aaronson, S. A.: Bovine lymphosarcoma: development of a sensitive radioimmunologic technique for detection of the etiologic agent. Science 194: 1428-1430, 1976.
138. Aaronson, S. A. and Stephenson, J. R.: Intracellular and systemic regulation of biologically distinguishable endogenous type C RNA viruses of mouse cells. In Hanna, M. G. and Rapp, F. (Eds.): Contemporary Topics in Immunobiology. New York, Plenum Publishing Corp., 1977, pp. 107-123.
139. Essex, M., Cotter, S. M., Sliski, A. H., Hardy, W. D., Jr., Stephenson, J. R., Aaronson, S. A., and Jarrett, O.: Horizontal transmission of feline leukemia virus under natural conditions in a feline leukemia cluster household. Int. J. Cancer 19: 90-96, 1977.
140. Stephenson, J. R., Barbacid, M., Tronick, S. R., Hino, S., and Aaronson, S. A.: Proteins of type C RNA tumor viruses. In Gallo, R. (Ed.): Cancer Research: Cell Biology, Molecular Biology and Tumor Virology. Cleveland, CRC Press, 1977, pp. 37-50.
141. Stephenson, J. R. and Aaronson, S. A.: Differential regulation of endogenous type C viruses of mouse cells. In Schlessinger, D. (Ed.): Microbiology 1977. Baltimore, Waverly Press, 1977, pp. 542-547.
142. Phillips, S. M., Stephenson, J. R., and Aaronson, S. A.: Genetic factors influencing mouse type C RNA virus induction by naturally occurring B-cell mitogens. J. Immunol. 118: 662-666, 1977.
143. Bensinger, W. I., Robbins, K. C., Greenberger, J. S., and Aaronson, S. A.: Different mechanisms for morphologic reversion of a clonal population of murine sarcoma virus-transformed nonproducer cells. Virology 77: 750-761, 1977.
144. Stephenson, J. R., Essex, M., Hino, S., Hardy, W. D., Jr., and Aaronson, S. A.: Feline oncornavirus-associated cell membrane antigen (FOCMA). VII. Distinction

between FOCMA and the major virion glycoprotein. Proc. Natl. Acad. Sci. USA 74: 1219-1223, 1977.

145. Essex, M., Stephenson, J. R., Hardy, W. D., Jr., Cotter, S. M., and Aaronson, S. A.: Leukemia, lymphoma and fibrosarcoma of cats as models for similar diseases of man. In Hiatt, H., Watson, J. D., and Winsten, J. A. (Eds.): Origins of Human Cancer. New York, Cold Spring Harbor Laboratory, 1977, pp. 1197-1209.
146. Stephenson, J. R. and Aaronson, S. A.: Endogenous type C viral expression in primates. Nature 266: 469-472, 1977.
147. Barbacid, M., Stephenson, J. R., and Aaronson, S. A.: Evolutionary relationships between gag gene-coded proteins of murine and primate endogenous type C RNA viruses. Cell 10: 641-648, 1977.
148. Peters, R. L., Sass, B., Stephenson, J. R., Al-Ghazzouli, I. K., Hino, S., Donahoe, R. M., Kende, M., Aaronson, S. A., and Kelloff, G. J.: Immunoprevention of X-ray induced leukemias in the C57BL mouse. Proc. Natl. Acad. Sci. USA 74: 1697-1701, 1977.
149. Krakower, J. M., Barbacid, M., and Aaronson, S. A.: Radio-immunoassay for mammalian type C viral reverse transcriptase. J. Virol. 22: 331-339, 1977.
150. Robbins, K. C., Cabradilla, C. D., Stephenson, J. R., and Aaronson, S. A.: Segregation of genetic information for a B-tropic leukemia virus with the structural locus for BALB:virus-l. Proc. Natl. Acad. Sci. USA 74: 2953-2957, 1977.
151. Tronick, S. R., Golub, M. M., Stephenson, J. R., and Aaronson, S. A.: Distribution and expression in mammals of genes related to an endogenous type C RNA virus of *Odocoileus hemionus*. J. Virol. 23: 1-9, 1977.
152. Reynolds, F. R., Jr., Hanson, C. A., Aaronson, S. A., and Stephenson, J. R.: Type C viral gag gene expression in chicken embryo fibroblasts and avian sarcoma virus transformed mammalian cells. J. Virol. 23: 74-79, 1977.
153. Krakower, J. M., Barbacid, M., and Aaronson, S. A.: Differential synthesis of mammalian type C viral gene products in infected cells. J. Virol. 24: 1-7, 1977.
154. Robbins, K. C., Stephenson, J. R., Cabradilla, C. D., and Aaronson, S. A.: Endogenous mouse type C RNA virus of SWR cells: inducibility locus containing structural information for a distinct endogenous virus class. Virology 82: 392-400, 1977.

155. Hino, S., Tronick, S. R., Heberling, R. L., Kalter, S. S., Hellman, A., and Aaronson, S. A.: Endogenous New World primate retrovirus: interspecies antigenic determinants shared with the major structural protein of type D RNA viruses of Old World monkeys. Proc. Natl. Acad. Sci. USA 74: 5734-5738, 1977.
156. Barbacid, M., Tronick, S. R., and Aaronson, S. A.: Isolation and characterization of an endogenous type C RNA virus of mink (MvLu) cells. J. Virol. 25: 129-137, 1978.
157. Robbins, K. C., Okabe, H., Tronick, S. R., Gilden, R. V., and Aaronson, S. A.: Molecular mechanisms involved in the differential expression of gene products by clonal isolates of a primate sarcoma virus. J. Virol. 26: 471-478, 1978.
158. Barbacid, M., Robbins, K. C., Hino, S., and Aaronson, S. A.: Genetic recombination between mouse type C RNA viruses: a mechanism for endogenous viral gene amplification in mammalian cells. Proc. Natl. Acad. Sci. USA 75: 923-927, 1978.
159. Barbacid, M. and Aaronson, S. A.: Membrane properties of the gag gene-coded p15 proteins of mouse type C RNA tumor viruses. J. Biol. Chem. 253: 1408-1414, 1978.
160. Krakower, J. M. and Aaronson, S. A.: Radioimmunologic characterization of RD-114 reverse transcriptase: evolutionary relatedness of mammalian type C viral pol gene products. Virology 86: 127-137, 1978.
161. Aaronson, S. A., Krakower, J. M., Tronick, S. R., and Stephenson, J. R.: Immunologic approaches toward detection of type C viral expression in man. Arthritis and Rheumatism 21: S27-S45, 1978.
162. Tronick, S. R., Cabradilla, C. D., Aaronson, S. A., and Haseltine, W. A.: 5'-terminal nucleotide sequences of mammalian type C helper viruses are conserved in the genomes of replication-defective mammalian transforming viruses. J. Virol. 26: 570-576, 1978.
163. Krakower, J. M. and Aaronson, S. A.: Seroepidemiologic assessment of feline leukemia virus infection risk for man. Nature 273: 463-464, 1978.
164. Aaronson, S. A. and Barbacid, M.: Origin and biological properties of a new BALB/c mouse sarcoma virus (BALB-MSV). J. Virol. 27: 366-373, 1978.
165. Lai, M-H .T., Verma, I. M., Tronick, S. R., and Aaronson, S. A.: Mammalian retrovirus-associated RNase H is virus-coded. J. Virol. 27: 823-825, 1978.

166. Barbacid, M., Troxler, D. H., Scolnick, E. M., and Aaronson, S. A.: Analysis of translational products of Friend strain of spleen focus-forming virus. J. Virol. 27: 826-830, 1978.
167. Israel, M. A., Martin, M. A., Takemoto, K. K., Howley, P. M., Aaronson, S. A., Solomon, D., and Khoury, G.: Evaluation of normal and neoplastic human tissue for BK virus. Virology 90: 187-196, 1978.
168. Aaronson, S. A., Barbacid, M., Hino, S., Tronick, S. R., and Krakower, J. M.: Common progenitors in the evolution of mammalian retroviruses: implications in the search for RNA tumor virus expression in man. In Bentvelzen, P., Hilgers, J., and Yohn, D. S. (Eds.): Advances in Comparative Leukemia Research, 1977. Amsterdam/New York, Elsevier/North Holland Biomedical Press, 1978, pp. 127-134.
169. Takemoto, K. K., Solomon, D., Israel, M., Howley, P. M., Khoury, G., Aaronson, S. A., and Martin, M. A.: Search for evidence of papovavirus involvement in human cancer. In Bentvelzen, P., Hilgers, J., and Yohn, D. S. (Eds.): Advances in Comparative Leukemia Research, 1977. Amsterdam/ New York, Elsevier/North Holland Biomedical Press, 1978, pp. 260-263.
170. Krakower, J. M., Tronick, S. R., Gallagher, R. E., Gallo, R. C., and Aaronson, S. A.: Antigenic characterization of a new gibbon ape leukemia virus isolate: seroepidemiologic assessment of an outbreak of gibbon leukemia. Int. J. Cancer 22: 715-720, 1978.
171. Barbacid, M., Robbins, K. C., and Aaronson, S. A.: Wild mouse RNA tumor viruses: a nongenetically transmitted virus group closely related to exogenous leukemia viruses of laboratory mouse strains. J. Exp. Med. 149: 254-266, 1979.
172. Porzig, K. J., Barbacid, M., and Aaronson, S. A.: Biological properties and translational products of three independent isolates of feline sarcoma virus. Virology 92: 91-107, 1979.
173. Andersen, P., Barbacid, M., Tronick, S. R., Clark, H. F., and Aaronson, S. A.: Evolutionary relatedness of viper and primate endogenous type D retroviruses. Science 204: 318-321, 1979.
174. Porzig, K. J., Robbins, K. C., and Aaronson, S. A.: Cellular regulation of mammalian sarcoma virus expression: A gene regulation model for oncogenesis. Cell 16: 875-884, 1979.

175. Canaani, E. and Aaronson, S. A.: Restriction enzyme analysis of mouse cellular type C viral DNA: emergence of new viral sequences in spontaneous AKR/J lymphomas. Proc. Natl. Acad. Sci. USA 76: 1677-1681, 1979.
176. Barbacid, M., Hunter, E., and Aaronson, S. A.: Avian reticuloendotheliosis viruses: evolutionary linkage with mammalian type C retroviruses. J. Virol. 30: 508-514, 1979.
177. Frankel, A., Gilbert, J., Larsen, D., Porzig, K., Scolnick, E. M., Fischinger, P., and Aaronson, S. A.: Nature and distribution of feline sarcoma virus nucleotide sequences. J. Virol. 30: 821-827, 1979.
178. Robbins, K. C., Barbacid, M., Porzig, K. J., and Aaronson, S. A.: Involvement of different exogenous feline leukemia virus subgroups in the generation of independent feline sarcoma virus isolates. Virology 97: 1-11, 1979.
179. Rosen, S. W., Kaminska, J., Calvert, I. S., and Aaronson, S. A.: Human fibroblasts produce "pregnancy-specific" beta-1 glycoprotein *in vitro*. Am. J. Obstet. Gynecol. 134: 734-738, 1979.
180. Canaani, E., Robbins, K. C., and Aaronson, S. A.: The transforming gene of Moloney murine sarcoma virus. Nature 282: 378-383, 1979.
181. Aaronson, S. A., Porzig, K. J., and Greenberger, J. S.: Mechanisms of reversion of mammalian sarcoma virus transformed cells. In Fox, M. (Ed.): Advances in Medical Oncology, Research and Education. Oxford/New York, Pergamon Press, 1979, pp. 75-85.
182. Barbacid, M., Steel, J., Long, L. K., and Aaronson, S. A.: Isolation and genetic analysis of mammalian type C RNA recombinant viruses. In Margison, G. P. (Ed.): Advances in Medical Oncology, Research and Education. Oxford/New York, Pergamon Press, 1979, pp. 43-49.
183. Tronick, S. R., Robbins, K. C., Canaani, E., Devare, S., Andersen, P. R., and Aaronson, S. A.: Molecular cloning of Moloney murine sarcoma virus: arrangement of virus-related sequences within the normal mouse genome. Proc. Natl. Acad. Sci. USA 76: 6314-6318, 1979.
184. Barbacid, M., Long, L. K., and Aaronson, S. A.: Major structural proteins of type B, type C, and type D oncoviruses share interspecies antigenic determinants. Proc. Natl. Acad. Sci. USA 77: 72-76, 1980.

185. Aaronson, S. A. and Barbacid, M.: Viral genes involved in leukemogenesis. I. Generation of recombinants between oncogenic and non-oncogenic mouse type C viruses in tissue culture. J. Exp. Med. 151: 467-480, 1980.
186. Dahlberg, J. R., Tronick, S. R., and Aaronson, S. A.: Immunological relationships of an endogenous guinea pig retrovirus with prototype mammalian type B and type D retroviruses. J. Virol. 33: 522-530, 1980.
187. Barbacid, M., Daniel, M. D., and Aaronson, S. A.: Immunological relationships of OMC-1, an endogenous virus of owl monkeys, with mammalian and avian type C viruses. J. Virol. 33: 561-566, 1980.
188. Reddy, P., Dunn, C. Y., and Aaronson, S. A.: Different lymphoid cell targets for transformation by replication-competent Moloney and Rauscher mouse leukemia viruses. Cell 19: 663-669, 1980.
189. Barbacid, M., Bolognesi, D. P., and Aaronson, S. A.: Humans have antibodies capable of recognizing oncoviral glycoproteins: demonstration that these antibodies are formed in response to cellular modification of glycoproteins rather than as consequence of exposure to virus. Proc. Natl. Acad. Sci. USA 77: 1617-1621, 1980.
190. Rosen, S. W., Weintraub, B. D., and Aaronson, S. A.: Nonrandom ectopic protein production by malignant cells: direct evidence *in vitro*. J. Clin. Endocrinol. Metab. 50: 834-841, 1980.
191. Canaani, E., Tronick, S. R., Robbins, K. C., Andersen, P. R., Dunn, C. Y., and Aaronson, S. A.: Cellular origin of the transforming gene of Moloney murine sarcoma virus. Cold Spring Harbor Symp. Quant. Biol. 44: 727-734, 1980.
192. Rosen, S. W., Kaminska, J., Calvert, I. S., Ellmore, N., and Aaronson, S. A.: Ectopic production of "pregnancy-specific" beta-1 glycoprotein *in vitro*: discordance with three other placental proteins. Amer. J. Obstet. Gynecol. 137: 525-529, 1980.
193. Canaani, E., and Aaronson, S. A.: Isolation and characterization of naturally occurring deletion mutants of Moloney murine sarcoma virus. Virology 105: 456-466, 1980.
194. Reddy, E. P., Smith, M. J., Canaani, E., Robbins, K. C., Tronick, S. R., Zain, S., and Aaronson, S. A.: Nucleotide sequence analysis of the transforming region and large terminal redundancies of Moloney-murine sarcoma virus. Proc. Natl. Acad. Sci. USA 77: 5234-5238, 1980.

195. Nagao, K., Yokoro, K., and Aaronson, S. A.: Continuous lines of basophil/mast cells derived from normal mouse bone marrow. Science 212: 333-335, 1981.
196. Barbacid, M., Krakower, J., and Aaronson, S. A.: Search for evidence of humoral immunity to oncoviruses in man. In Todaro, G. J. and Essex, M. (Eds.): Viruses in Naturally Occurring Cancers. New York, Cold Spring Harbor Laboratory Press, 1980, pp. 869-883.
197. Gardner, M. B., Barbacid, M., Rasheed, S., Grant, C., and Aaronson, S. A.: Humoral immunity in natural FeLV-exposed and experimental FeSV-inoculated house cats. In Hardy, W. D., Essex, M., and McClelland, A. J. (Eds.): Feline Leukemia Virus. New York, Elsevier/North Holland Press, 1980, pp. 159-169.
198. Oroszlan, S., Barbacid, M., Copeland, T. D., and Aaronson, S. A.: Chemical and immunological characterization of the major structural protein (p28) of MMC-1, a Rhesus monkey endogenous type C virus: homology with the major structural protein of avian reticuloendotheliosis virus. J. Virol. 39: 845-854, 1981.
199. Srinivasan, A., Reddy, E. P., and Aaronson, S. A.: Abelson murine leukemia virus: molecular cloning of infectious integrated proviral DNA. Proc. Natl. Acad. Sci. USA 78: 2077-2081, 1981.
200. Cremer, K., Reddy, E. P., and Aaronson, S. A.: Translational products of Moloney murine sarcoma virus RNA: identification of proteins encoded by the murine sarcoma virus src gene. J. Virol. 38: 704-711, 1981.
201. Robbins, K. C., Devare, S. G., and Aaronson, S. A.: Molecular cloning of integrated simian sarcoma virus: Genome organization of infectious DNA clones. Proc. Natl. Acad. Sci. USA 78: 2918-2922, 1981.
202. Aaronson, S. A., Barbacid, M., Dunn, C. Y., and Reddy, E. P.: Genetic approaches toward elucidating the mechanisms of type C virus induced leukemia. In Neth, R. (Ed.): Modern Trends in Human Leukemia. Berlin/Heidelberg, Springer-Verlag, 1981, pp. 455-459.
203. Merregaert, J., Barbacid, M., and Aaronson, S. A.: Recombinants between temperature-sensitive mutants of Rauscher murine leukemia virus and BALB:virus-2: genetic mapping of the Rauscher murine leukemia virus genome. J. Virol. 39: 219-228, 1981.
204. Andersen, P. R., Devare, S. G., Tronick, S. R., Ellis, R. W., Aaronson, S. A., and Scolnick, E. M.: Generation of BALB-MuSV and Ha-MuSV by type C virus transduction of homologous transforming genes from different species. Cell 26: 129-134, 1981.

205. Reddy, E. P., Smith, M. J., and Aaronson, S. A.: Complete nucleotide sequence and organization of the Moloney murine sarcoma virus genome. Science 214: 445-450, 1981.
206. Andersen, P. R., Tronick, S. R., and Aaronson, S. A.: Structural organization and biological activity of molecular clones of the integrated genome of a BALB/c mouse sarcoma virus (BALB-MSV). J. Virol. 40: 431-439, 1981.
207. Eva, A., Robbins, K. C., Andersen, P. R., Srinivasan, A., Tronick, S. R., Reddy, E. P., Ellmore, N. W., Galen, A. T., Lautenberger, J. A., Papas, T. S., Westin, E. H., Wong-Staal, F., Gallo, R. C., and Aaronson, S. A.: Cellular genes analogous to retroviral *onc* genes are transcribed in human tumor cells. Nature 295: 116-119, 1982.
208. Robbins, K. C., Hill, R. L., and Aaronson, S. A.: Primate origin of the cell-derived sequences of simian sarcoma virus. J. Virol. 41: 721-725, 1982.
209. Rasheed, S., Barbacid, M., Aaronson, S. A., and Gardner, M. B.: Origin and biological properties of a new feline sarcoma virus. Virology 117: 238-244, 1982.
210. Westin, E. H., Gallo, R. C., Arya, S. K., Eva, A., Souza, L. M., Baluda, M. A., Aaronson, S. A., and Wong-Staal, F.: Differential expression of the *amv* gene in human hematopoietic cells. Proc. Natl. Acad. Sci. USA 79: 2194-2198, 1982.
211. Westin, E. H., Wong-Staal, F., Gelmann, E. P., Dalla-Favera, R. C., Papas, T. S., Lautenberger, J. A., Eva, A., Reddy, E. P., Tronick, S. R., Aaronson, S. A., and Gallo, R. C.: Expression of cellular homologs of retroviral *onc* genes in human hematopoietic cells. Proc. Natl. Acad. Sci. USA 79: 2490-2494, 1982.
212. Devare, S. G., Reddy, E. P., Robbins, K. C., Andersen, P. R., Tronick, S. R., and Aaronson, S. A.: Nucleotide sequence of the transforming gene of simian sarcoma virus. Proc. Natl. Acad. Sci. USA 79: 3179-3182, 1982.
213. Devare, S. G., Reddy, E. P., Law, J. D., and Aaronson, S. A.: Nucleotide sequence analysis of the long terminal repeat (LTR) of integrated simian sarcoma virus: evolutionary relationship with other mammalian retroviral LTRs. J. Virol. 42: 1108-1113, 1982.
214. Eva, A., Robbins, K. C., Andersen, P. R., Srinivasan, A., Tronick, S. R., Reddy, E. P., Ellmore, N. W., Galen, A. T., Lautenberger, J. A., Papas, T. S., Westin, E. W., Wong-Staal, F., Gallo, R. C., and Aaronson, S. A.: Transcription of retrovirus *onc* gene and analogues in human solid tumor cells. In Yohn, D. S., and Blakeslee, J.

R. (Eds.): Advances in Comparative Leukemia Research 1981. New York/Amsterdam, Elsevier Biomedical, 1981, pp. 381-382.

215. Westin, E., Wong-Staal, F., Gelmann, E., Baluda, M., Papas, T., Eva, A., Reddy, E. P., Tronick, S. R., Aaronson, S. A., and Gallo, R. C.: Expression of the *abl*, *myc*, and *amv* genes in human hematopoietic cells. In Yohn, D. S. and Blakeslee, J. R. (Eds.): Advances in Comparative Leukemia Research 1981. New York/Amsterdam, Elsevier Biomedical, 1981, pp. 405-406.
216. Swan, D. C., McBride, O. W., Robbins, K. C., Keithley, D. A., Reddy, E. P., and Aaronson, S. A.: Chromosomal mapping of the simian sarcoma virus *onc* gene analogue in human cells. Proc. Natl. Acad. Sci. USA 79: 4691-4695, 1982.
217. Aaronson, S. A., Storch, T. G., Balachandra, R., and Reddy, E. P.: Different hematopoietic target cells for transformation by replication-competent murine leukemia viruses. In Marchesi, V.T. and Gallo, R. C. (Eds.): Progress in Clinical and Biological Research: Differentiation and Function of Hematopoietic Cell Surfaces. New York, Allen R. Liss, Inc., 1982, pp. 251-261.
218. Santos, E., Tronick, S. R., Aaronson, S. A., Pulciani, S., and Barbacid, M.: The T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature 298: 343-347, 1982.
219. Pierce, J. and Aaronson, S. A.: BALB- and Harvey-MSV transformation of a novel lymphoid progenitor cell. J. Exp. Med. 156: 873-887, 1982.
220. Prakash, K., McBride, O. W., Swan, D. C., Devare, S. G., Tronick, S. R., and Aaronson, S. A.: Molecular cloning and chromosomal mapping of a human locus related to the transforming gene of moloney murine sarcoma virus. Proc. Natl. Acad. Sci. USA 79: 5210-5214, 1982.
221. Srinivasan, A., Dunn, C. Y., Yuasa, Y., Devare, S. G., Reddy, E. P., and Aaronson, S. A.: Abelson murine leukemia virus: structural requirements for transforming gene function. Proc. Natl. Acad. Sci. USA 79: 5508-5512, 1982.
222. Habara, A., Reddy, E. P., and Aaronson, S. A.: Rauscher-murine leukemia virus: molecular cloning of infectious integrated proviral DNA. J. Virol. 44: 731-735, 1982.
223. Merregaert, J. and Aaronson, S. A.: Characterization of inducible type C RNA viruses of mouse strains from different geographic areas. Virology 123: 165-17, 1982.

224. Robbins, K. C., Devare, S. G., Reddy, E. P., and Aaronson, S. A.: *In vivo* identification of the transforming gene product of simian sarcoma virus. Science 218: 1131-1133, 1982.
225. Pulciani, S., Santos, E., Lauver, A. V., Long, L. K., Aaronson, S. A., and Barbacid, M.: Oncogenes in solid human tumors. Nature 300: 539-542, 1982.
226. McBride, O. W., Swan, D. C., Santos, E., Barbacid, M., Tronick, S. R., and Aaronson, S. A.: Localization of the normal allele of T24 human bladder carcinoma oncogene to chromosome 11. Nature 300: 773-774, 1982.
227. Taub, R., Kirsch, I., Morton, C., Lenoir, G., Swan, D., Tronick, S. R., Aaronson, S. A., and Leder, P.: Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt's lymphoma and murine plasmacytoma cells. Proc. Natl. Acad. Sci. USA 79: 7837-7841, 1982.
228. Aaronson, S. A.: Unique aspects of the interactions of retroviruses with vertebrate cells: C. P. Rhoads Memorial Lecture. Cancer Res. 43: 1-5, 1983.
229. Devare, S. G., Reddy, E. P., Law, D. J., Robbins, K. C., and Aaronson, S. A.: Nucleotide sequence of the simian sarcoma virus genome: demonstration that its acquired cellular sequences encodes the putative transforming gene product, p28^{sis}. Proc. Natl. Acad. Sci. USA 80: 731-735, 1983.
230. Weissman, B. E. and Aaronson, S. A.: BALB and Kirsten murine sarcoma viruses alter growth and differentiation of EGF-dependent BALB/c mouse epidermal keratinocyte lines. Cell 32: 599-606, 1983.
231. Aaronson, S. A., Dunn, C. Y., Ellmore, N. W., and Eva, A.: Retroviral onc genes in human neoplasia. In O'Connor, T.E. and Rauscher, F.J. (Eds.): Oncogenes and Retroviruses: Evaluation of Basic Findings and Clinical Potential. New York, Alan R. Liss, Inc., 1983, pp. 207-222.
232. Pierce, J. H. and Aaronson, S. A.: *In vitro* transformation of murine pre-B lymphoid cells by Snyder-Theilen feline sarcoma virus. J. Virol. 46: 993-1002, 1983.
233. Eva, A. and Aaronson, S. A.: Frequent activation of c-kis as a transforming gene in fibrosarcomas induced by methylcholanthrene. Science 220: 955-956, 1983.
234. Yuasa, Y., Srivastava, S. K., Dunn, C. Y., Rhim, J. S., Reddy, E. P., and Aaronson, S. A.: Acquisition of transforming properties by alternative point mutations within c-bas/has human proto-oncogene. Nature 303: 775-779, 1983.

235. Doolittle, R. F., Hunkapiller, M. W., Hood, L. E., Devare, S. G., Robbins, K. C., Aaronson, S. A., and Antoniades, H. N.: Simian sarcoma *onc* gene, *v-sis*, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science 221: 275-277, 1983.
236. Eva, A., Tronick, S. R., Gol, R. A., Pierce, J. H., and Aaronson, S. A.: Transforming genes of human hematopoietic tumors: frequent detection of *ras*-related oncogenes whose activation appears to be independent of tumor phenotype. Proc. Natl. Acad. Sci. USA 80: 4926-4930, 1983.
237. Naharro, G., Tronick, S. R., Rasheed, S., Gardner, M. B., Aaronson, S. A., and Robbins, K. C.: Molecular cloning of integrated Gardner-Rasheed feline sarcoma virus: genetic structure of its cell-derived sequence differs from that of other tyrosine kinase coding *onc* genes. J. Virol. 47: 611-619, 1983.
238. Needleman, S., Yuasa, Y., Srivastava, S., and Aaronson, S. A.: Normal cells of patients with high cancer risk syndromes lack transforming activity in the NIH/3T3 transfection assay. Science 222: 173-175, 1983.
239. Robbins, K. C., Antoniades, H. N., Devare, S. G., Hunkapiller, M. W., and Aaronson, S. A.: Structural and immunological similarities between simian sarcoma virus gene product(s) and human platelet-derived growth factor. Nature 305: 605-608, 1983.
240. Chiu, I. M., Andersen, P. R., Aaronson, S. A., and Tronick, S. R.: Molecular cloning of the unintegrated squirrel monkey retrovirus genome: organization and distribution of related sequences in primate DNAs. J. Virol. 47: 434-411, 1983.
241. Aaronson, S. A., Reddy, E. P., Robbins, K. C., Devare, S. G., Swan, D. C., Pierce, J. H., and Tronick, S. R.: Retroviruses, *onc* genes and human cancer. In Harris, C. C. and Autrup, H. N. (Eds.): Human Carcinogenesis. New York, Academic Press, 1983, pp. 609-630.
242. McBride, O. W., Swan, D. C., Tronick, S. R., Gol, R., Klimanis, D., Moore, D. E., and Aaronson, S. A.: Regional chromosomal localization of *N-ras*, *K-ras-1*, *K-ras-2* and *myb* oncogenes in human cells. Nucleic Acids Res. 11: 8221-8236, 1983.
243. Devare, S. G., Shatzman, A., Robbins, K. C., Rosenberg, M., and Aaronson, S. A.: Expression of the PDGF-related transforming protein of simian sarcoma virus in *E. coli*. Cell 36: 43-49, 1984.
244. Chiu, I. M., Callahan, R., Tronick, S. R., Schlom, J., and Aaronson, S. A.: Major *pol* gene progenitors in the evolution of oncoviruses. Science 223: 364-370, 1984.

245. Srinivasan, A., Reddy, E. P., Dunn, C. Y., and Aaronson, S. A.: Molecular dissection of transcriptional control elements within the long terminal repeat of the retrovirus. Science 223: 286-289, 1984.
246. Chiu, I.-M., Reddy, E. P., Givol, D., Robbins, K. C., Tronick, S. R., and Aaronson, S. A.: Nucleotide sequence analysis identifies the human c-sis proto-oncogene as a structural gene for platelet-derived growth factor. Cell 37: 123-129, 1984.
247. Tronick, S. R. and Aaronson, S. A.: Unique interactions of retroviruses with eukaryotic cells. In Notkins, A. L. and Oldstone, M. B. A. (Eds.): Concepts in Viral Pathogenesis. New York, Springer-Verlag, 1984, pp. 165-171.
248. McBride, O. W., Swan, D. S., Robbins, K. C., Prakash, K., and Aaronson, S. A.: Chromosomal mapping of tumor virus transforming gene analogues in human cells. In Pearson, M. L. and Sternberg, N. L. (Eds.): Gene Transfer and Cancer 1982. New York, Raven Press, 1984, pp. 197-205.
249. Pierce, J. H., Aaronson, S. A., and Anderson, S. M.: Hematopoietic cell transformation by a murine recombinant retrovirus containing the src gene of Rous sarcoma virus. Proc. Natl. Acad. Sci. USA 81: 2374-2378, 1984.
250. Fujita, J., Yoshida, O., Yuasa, Y., Rhim, J. S., Hatanaka, M., and Aaronson, S. A.: Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours. Nature 309: 464-466, 1984.
251. Yuasa, Y., Gol, R. A., Chang, A., Chiu, I.-M., Reddy, E. P., Tronick, S. R., and Aaronson, S. A.: Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells. Proc. Natl. Acad. Sci. USA 81: 3670-3674, 1984.
252. Robbins, K. C., Antoniades, H. N., Devare, S. G., Hunkapiller, M. W., and Aaronson, S. A.: Close similarities between the transforming gene product of simian sarcoma virus and human platelet-derived growth factor. In Arnold, J. L., Vande Woude, G. F., Topp, W. C. and Watson, J. D. (Eds.): Cancer Cells 1/The Transformed Phenotype. New York, Cold Spring Harbor Laboratory, 1984, pp. 35-42.
253. Yuasa, Y., Eva, A., Kraus, M. H., Srivastava, S. K., Needleman, S. W., Pierce, J. H., Rhim, J. S., Gol, R., Reddy, E. P., Tronick, S. R., and Aaronson, S. A.: ras-related oncogenes of human tumors. In Vande Woude, G. F., Levine, A. J., Topp, W. C. and Watson, J. D. (Eds.): Cancer Cell 2/Oncogenes and Viral Genes. New York, Cold Spring Harbor Laboratory, 1984, pp. 433-439.

254. Narayanan, R., Srinivasan, A., and Aaronson, S. A.: Sequences in the long terminal repeats of the Moloney murine sarcoma virus-124 genome which control transforming gene function. Virology 137: 32-40, 1984.
255. Kraus, M., Yuasa, Y., and Aaronson, S. A.: A position 12-activated H-ras oncogene in all HS578T mammary carcinosarcoma cells but not normal mammary cells of the same patient. Proc. Natl. Acad. Sci. USA 81: 5384-5388, 1984.
256. Aaronson, S. A., Yuasa, Y., Robbins, K. C., Eva, A., Gol, R., and Tronick, S. R.: Oncogenes and the neoplastic process. In Aaronson, S. A., Frati, L. and Verna, R. (Eds.): Genetic and Phenotypic Markers of Tumors. New York, Plenum Press, 1984, pp. 261-278.
257. Pierce, J. H. and Aaronson, S. A.: Interaction of acute transforming retroviruses with murine hematopoietic cells. In Potter, M., Melchers, F. and Weigert, M. (Eds.): Oncogenes and B-Cell Neoplasia. Current Topics in Microbiology and Immunology. Berlin/Heidelberg, Springer-Verlag, 1984, pp. 258-264.
258. Eva, A. and Aaronson, S. A.: Identification and preliminary characterization of a new transforming gene from a human lymphoma. In Bishop, J. M., Rowley, J. D. and Greaves, M. (Eds.): Genes and Cancer. UCLA Symposia on Molecular and Cellular Biology. New York, Alan R. Liss, Inc., 1984, pp. 373-382.
259. Aaronson, S. A.: Transforming genes of retroviruses and human cancer cells. In Fortner, J. G. and Rhoads, J. E. (Eds.): Accomplishments in Cancer Research, 1983. Philadelphia, J. B. Lippincott Company, 1984, pp. 139-150.
260. Gazit, A., Igarashi, H., Chiu, I.-M., Srinivasan, A., Yaniv, A., Tronick, S. R., Robbins, K. C., and Aaronson, S. A.: Expression of the normal human *sis*/PDGF-2 coding sequence induces cellular transformation. Cell 39: 89-97, 1984.
261. Pierce, J. H., Eva, A., and Aaronson, S. A.: Hematopoietic cell targets for transformation by retroviral oncogenes. In Peschle, C. and Rizzoli, C. (Ed.): New Trends in Experimental Hematology. Rome, Italy, Ares Serono Symposia, 1984, pp. 1-18.
262. Aaronson, S. A., Frati, L., and Verna, R. (Eds.): Genetic and Phenotypic Markers of Tumors. New York, Plenum Press, 1984, 379 pp.
263. Balachandran, R., Reddy, E. P., Dunn, C. Y., Aaronson, S. A., and Swan, D.: Immunoglobulin synthesis and gene rearrangements in lymphoid cells transformed by replication-competent Rauscher murine leukemia virus:

transformation of B cells at various stages of differentiation. EMBO J. 3: 3199-3207, 1984.

264. Aaronson, S. A., Robbins, K. C., and Tronick, S. R.: Human proto-oncogenes, growth factors, and cancer. In Ford, R. J. and Maizel, A. L. (Eds.): Mediators in Cell Growth and Differentiation. New York, Raven Press, 1985, pp. 241-255.
265. Aaronson, S. A. and Tronick, S. R.: The role of oncogenes in human neoplasia. In Devita, V. T., Hellman, S., and Rosenberg, S. A. (Eds.): Important Advances in Oncology 1985. Philadelphia, J. B. Lippincott Co., 1985, pp. 3-15.
266. Srivastava, S. K., Yuasa, Y., Reynolds, S. H., and Aaronson, S. A.: Effects of two major activating lesions on the structure and conformation of human *ras* oncogene products. Proc. Natl. Acad. Sci. USA. 82: 38-42, 1985.
267. Rhim, J. S., Jay, G., Arnstein, P., Price, F. M., Sanford, K. K., and Aaronson, S. A.: Neoplastic transformation of human epidermal keratinocytes by AD12-SV40 and Kirsten sarcoma viruses. Science 227: 1250-1252, 1985.
268. Aaronson, S. A. and Robbins, K. C.: Activation of a gene coding for a normal human growth factor to one with transforming properties. In Furmanski, P., Hager, J. C. and Rich, M. A. (Eds.): RNA Tumor Viruses, Oncogenes Human Cancer and AIDS: On the Frontiers of Understanding. Boston, Martinus Nijhoff Publishing, 1985, pp. 54-66.
269. Reddy, E. P., Lipman, D., Andersen, P. R., Tronick, S. R., and Aaronson, S. A.: Nucleotide sequence analysis of the BALB/c murine sarcoma virus transforming gene. J. Virol. 53: 984-987, 1985.
270. Tronick, S. R., Yuasa, Y., Robbins, K. C., Eva, A., Gol, R., and Aaronson, S. A.: Oncogene research: closing in on a better understanding of cancer causation. In Selikoff, I. J., Teirstein, A. S. and Hirschman, S. Z. (Eds.): Acquired Immune Deficiency Syndrome. New York, The New York Academy of Sciences, 1984, pp. 150-160.
271. Igarashi, H., Gazit, A., Chiu, I.-M., Srinivasan, A., Yaniv, A., Tronick, S. R., Robbins, K. C., and Aaronson, S. A.: Expression of a normal growth factor gene causes morphologic transformation. In Giraldo, E., Beth, E., Castello, G., Giordano, G. G., and Zarrilli, D. (Eds.): From Oncogenes to Tumor Antigens. Amsterdam, Elsevier, 1985, pp. 3-15.
272. Aaronson, S. A., Tronick, S. R., and Robbins, K. C.: Oncogenes and pathways to malignancy. In Boynton, A. L. and Leffert, H. L. (Eds.): Control of Animal Cell Proliferation. New York, Academic Press, 1985, pp. 3-24.

273. Pierce, J. H. and Aaronson, S. A.: Myeloid cell transformation by *ras*-containing murine sarcoma viruses. Mol. Cell. Biol. 5: 667-674, 1985.
274. Callahan, R., Chiu, I.-M., Horn T., Ali, I., Robbins, J., Aaronson, S. A., and Schlom, J.: A new class of human endogenous retroviral genes. In Rich, M. (Ed.): RNA Tumor Viruses in Human Cancer. Denver, Martinus Nijhoff Publishing, 1985, pp. 76-92.
275. Callahan, R., Chiu, I.-M., Wong, J. F. H., Tronick, S. R., Roe, B. A., Aaronson, S. A., and Schlom, J.: A new class of endogenous human retroviral genomes. Science 228: 1208-1211, 1985.
276. Fujita, J., Srivastava, S. K., Kraus, M. H., Rhim, J. S., Tronick, S. R., and Aaronson, S. A.: Frequency of molecular alterations affecting *ras* proto-oncogenes in human urinary tract tumors. Proc. Natl. Acad. Sci. USA 82: 3849-3853, 1985.
277. Igarashi, H., Gazit, A., Chiu, I.-M., Srinivasan, A., Yaniv, A., Tronick, S. R., Robbins, K. C., and Aaronson, S. A.: Normal human *sis*/PDGF-2 gene expression induces cellular transformation. In Feramisco, J., Ozanne, B., and Stiles, C. (Eds.): Cancer Cells 3/Growth Factors and Transformation. New York, Cold Spring Harbor Laboratories, 1985, pp. 159-166.
278. Eva, A. and Aaronson, S. A.: Isolation of a new human oncogene from a diffuse B-cell lymphoma. Nature 316: 273-275, 1985.
279. Pierce, J. H., Di Fiore, P. P., Aaronson, S. A., Potter, M., Pumphrey, J., Scott, A., and Ihle, J. N.: Neoplastic transformation of mast cells by Abelson-MuLV: Abrogation of IL-3 dependence by a nonautocrine mechanism. Cell 41: 685-693, 1985.
280. Chiu, I.-M., Huang, R.-C. C., and Aaronson, S. A.: Genetic relatedness between intracisternal A particles and other major oncovirus genera. Virus Res. 3: 1-11, 1985.
281. Popescu, N. C., Amsbaugh, S. C., DiPaolo, J. A., Tronick, S. R., Aaronson, S. A., and Swan, D. C.: Chromosomal localization of three human *ras* genes by *in situ* molecular hybridization. Somatic Cell and Mol. Genet. 11: 149-155, 1985.
282. Robbins, K. C., Leal, F., Pierce, J. H., and Aaronson, S. A.: The v-*sis*/PDGF-2 transforming gene product localizes to cell membranes but is not a secretory protein. EMBO J. 4: 1783-1792, 1985.

283. Yaniv, A., Dahlberg, J. E., Tronick, S. R., Chiu, I.-M., and Aaronson, S. A.: Molecular cloning of integrated caprine arthritis-encephalitis virus. Virology 145: 340-345, 1985.
284. King, C. R., Giese, N. A., Robbins, K. C. and Aaronson, S. A.: *In vitro* mutagenesis of the v-sis transforming gene defines functional domains of its growth factor-related product. Proc. Natl. Acad. Sci. USA 82: 5295-5299, 1985.
285. Aaronson, S. A. and Tronick, S. R.: Transforming genes of human malignancies. In Huberman, E. and Barr, S. H. (Eds.): The Role of Chemicals and Radiation in the Etiology of Cancer. Carcinogenesis: A Comprehensive Survey. New York, Raven Press, 1985, pp. 35-49.
286. King, C. R., Kraus, M. H., and Aaronson, S. A.: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974-976, 1985.
287. Rhim, J. S., Sanford, K. K., Arnstein, P., Fujita, J., Jay, G., and Aaronson, S. A.: Human epithelial cell carcinogenesis: combined action of DNA and RNA tumor viruses produces malignant transformation of primary human epidermal keratinocytes. In Barrett, J. C. and Tennant, R. W. (Eds.): Carcinogenesis. New York, Raven Press, 1985, pp. 57-66.
288. Chiu, I.-M., Yaniv, A., Dahlberg, J. E., Gazit, A., Skuntz, S., Tronick, S. R., and Aaronson, S. A.: Nucleotide sequence evidence for relationship of AIDS retrovirus to lentiviruses. Nature 317: 366-368, 1985.
289. Leal, F., William, L. T., Robbins, K. C., and Aaronson, S. A.: Evidence that the v-sis gene product transforms by interaction with the receptor for platelet-derived growth factor. Science 230: 327-330, 1985.
290. Srivastava, S. K., Lacal, J. C., Reynolds, S. H., and Aaronson, S. A.: Antibody of predetermined specificity to a carboxy-terminal region of H-ras gene products inhibits their guanine nucleotide-binding function. Mol. Cell. Biol. 5: 3316-3319, 1985.
291. Robbins, K. C., Igarashi, H., Gazit, A., Chiu, I.-M., Tronick, S. R., and Aaronson, S. A.: Establishing the link between human proto-oncogenes and growth factors. In Castellani, A. (Ed.): Epidemiology and Quantitation of Environmental Risk in Humans from Radiation and Other Agents. New York, Plenum Press, 1985, pp. 459-470.
292. Weissman, B. and Aaronson, S. A.: Members of the src and ras oncogene families supplant the epidermal growth factor requirement of BALB/MK-2 keratinocytes

and induce distinct alterations in their terminal differentiation program. Mol. Cell. Biol. 5: 3386-3396, 1985.

293. King, C. R., Giese, N. A., Kraus, M. H., Robbins, K. C., and Aaronson, S. A.: Oncogenes as growth factors and growth factor receptors: genetic studies of v-sis and a novel *erbB*-related gene. In Galeotti, T., Cittadini, A., Neri, G., Papa, S., and Smets, L. A. (Eds.): Cell Membranes and Cancer. Amsterdam, Elsevier Science Publishers, 1985, pp. 411-416.
294. Eva, A., Pierce, J. H., and Aaronson, S. A.: Interactions of oncogenes with hematopoietic cells. In Gale, R. P. and Golde, D. W. (Eds): Leukemia: Recent Advances in Biology and Treatment. New York, Alan R. Liss, Inc., 1985, pp. 3-15.
295. King, C. R., Kraus, M. H., Williams, L. T., Merlino, G. T., Pastan, I. H., and Aaronson, S. A.: Human tumor cell lines with EGF receptor gene amplification in the absence of aberrant sized mRNAs. Nucleic Acids Res. 13: 8477-8486, 1985.
296. Eva, A., Aaronson, S. A., and Tronick, S. R.: Transforming genes of human malignancies. In Pullman, B. et al. (Eds.): Interrelationship Among Aging, Cancer and Differentiation. Holland, D. Reidel Publishing Co., 1985, pp. 43-57.
297. Needleman, S. W., Kraus, M. H., Srivastava, S. K., Levine, P. H., and Aaronson, S. A.: High frequency of N-ras activation in acute myelogenous leukemia. Blood 67: 753-757, 1986.
298. Lacal, J. C., Srivastava, S. K., Anderson, P. S., and Aaronson, S. A.: Ras p21 proteins with high or low GTPase activity can efficiently transform NIH/3T3 cells. Cell 44: 609-617, 1986.
299. Lacal, J. C., Anderson, P. S., and Aaronson, S. A.: Deletion mutants of Harvey ras p21 protein reveal the absolute requirement of at least two distant regions for GTP-binding and transforming activities. EMBO. J. 5: 679-687, 1986.
300. Rhim, J. S., Fujita, J., Arnstein, P., and Aaronson, S. A.: Neoplastic conversion of human keratinocytes by adenovirus 12-SV40 virus and chemical carcinogens. Science 232: 385-388, 1986.
301. Rao, C. D., Igarashi, H., Chiu, I.-M., Robbins, K. C., and Aaronson, S. A.: Structure and sequence of the human c-sis/platelet-derived growth factor 2 (sis/PDGF2) transcriptional unit. Proc. Natl. Acad. Sci. USA 83: 2392-2396, 1986.

302. Lacal, J. C. and Aaronson, S. A.: Monoclonal antibody Y13-259 recognizes an epitope of the p21 *ras* molecule not directly involved in the GTP-binding activity of the protein. Mol. Cell. Biol. 6: 1002-1009, 1986.
303. Lacal, J. C. and Aaronson, S. A.: *ras* p21 deletion mutants and monoclonal antibodies as tools for localization of regions relevant to p21 function. Proc. Natl. Acad. Sci. USA 83: 5400-5404, 1986.
304. Yuasa, Y., Reddy, E. P., Rhim, J. S., Tronick, S. R., and Aaronson, S. A.: Activated N-*ras* in a human rectal carcinoma cell line associated with clonal homozygosity in *myb* locus-restriction fragment polymorphism. Jpn. J. of Cancer Res. 77: 639-647, 1986.
305. Leal, F., Igarashi, H., Gazit, A., Williams, L. T., Notario, V., Tronick, S. R., Robbins, K. C., and Aaronson, S. A.: Mechanism of transformation by an oncogene coding for a normal growth factor. In Harris, C. C. (Ed.): Biochemical and Molecular Epidemiology of Cancer. UCLA Symposia on Molecular and Cellular Biology. New York, Alan R. Liss, Inc., 1986, pp. 155-165.
306. Vecchio, G., Di Fiore, P. P., Fusco, A., Coletta, G., Weissman, B. E., and Aaronson, S. A.: *In vitro* transformation of epithelial cells by acute retroviruses. In Blasi, F. (Ed.): Human Genes and Diseases. Horizons in Biochemistry and Biophysics. Chichester, England, John Wiley & Sons Ltd., 1986, pp. 415-470.
307. Yaniv, A., Dahlberg, J., Gazit, A., Sherman, L., Chiu, I.-M., Tronick, S. R., and Aaronson, S. A.: Molecular cloning and physical characterization of integrated equine infectious anemia virus: molecular and immunologic evidence of its close relationship to ovine and caprine lentiviruses. Virology 154: 1-8, 1986.
308. Robbins, K. C., King, C. R., Giese, N. A., Leal, F., Igarashi, H. and Aaronson, S. A.: Involvement of oncogene-coded growth factors in the neoplastic process. In Papas, T. S. and Vande Woude, G. F. (Eds.): Gene Amplification and Analysis. Oncogenes. New York, Elsevier, 1986, pp. 161-176.
309. Robbins, K. C. and Aaronson, S. A.: Elucidation of a normal function for a human proto-oncogene. In Luderer, A. A. and Weetall, H. H. (Eds.): The Human Oncogenic Viruses. Molecular Analysis and Diagnosis. New Jersey, Humana Press, Inc., 1986, pp. 89-112.
310. Gazit, A., Pierce, J. H., Kraus, M. H., Di Fiore, P. P., Pennington, C. Y., and Aaronson, S. A.: Mammalian cell transformation by a murine retrovirus vector containing the avian erythroblastosis virus *erbB* gene. J. Virol. 60: 19-28, 1986.

311. Pierce, J. H., Gazit, A., Di Fiore, P. P., Kraus, M. H., Pennington, C. Y., Holmes, K. L., Davidson, W. F., Morse III, H. C., and Aaronson, S. A.: Mammalian cell transformation by a recombinant murine retrovirus containing the avian erythroblastosis virus *erbB* gene. In Potter, M. (Ed.): Current Topics in Microbiology and Immunology. Berlin/Heidelberg, Springer-Verlag, 1986, pp. 55-61.
312. Pierce, J. H., Eva, A., and Aaronson, S. A.: Interactions of oncogenes with hematopoietic cells. In Gale, R. P., and Hoffbrand, A. V. (Eds): Clinics in Haematology. Acute Leukaemia. London/Philadelphia/Toronto, W. B. Saunders Co., 1986, pp. 573-596.
313. Srivastava, S. K., Wheelock, R. H. P., Aaronson, S. A., and Eva, A.: Identification of the protein encoded by the human diffuse B-cell lymphoma (*dbl*) oncogene. Proc. Natl. Acad. Sci. USA 83: 8868-8872, 1986.
314. Tronick, S. R. and Aaronson, S. A.: Oncogenes, growth factors, and receptors. In Notkins, A. and Oldstone, M. (Eds.): Concepts in Viral Pathogenesis 11. New York, Springer-Verlag, 1986, pp. 98-109.
315. Lacal, J. C. and Aaronson, S. A.: Activation of *ras* p21 transforming properties associated with an increase in the release rate of bound guanine nucleotide. Mol. Cell Biol. 6: 4214-4220, 1986.
316. Pasti, G., Lacal, J. C., Warren, B. S., Aaronson, S. A., and Blumberg, P. M.: Loss of mouse fibroblast cell response to phorbol esters restored by microinjected protein kinase C. Nature 324: 375-377, 1986.
317. Kruh, G. D., King, C. R., Kraus, M. H., Popescu, N. C., Amsbaugh, S. C., McBride, W. O., and Aaronson, S. A.: A novel human gene closely related to the *abl* proto-oncogene. Science 234: 1545-1548, 1986.
318. Reynolds, S. H., Stowers, S. J., Maronpot, R. R., Anderson, M. W., and Aaronson, S. A.: Detection and identification of activated oncogenes in spontaneously occurring benign and malignant hepatocellular tumors of the B6C3F1 mouse. Proc. Natl. Acad. Sci. USA 83: 33-37, 1986.
319. Igarashi, H., Rao, C. D., Siroff, M., Leal, F., Robbins, K. C., and Aaronson, S. A.: Detection of PDGF-2 homodimers in human tumor cells. Oncogene 1: 79-85, 1987.
320. Rao, C. D., Igarashi, H., Pech, M. W., Robbins, K. C., and Aaronson, S. A.: Oncogenic potential of the human platelet-derived growth factor transcriptional unit. Cold Spring Harbor Symp. Quant. Biol. 51: 959-966, 1987.

321. Dahlberg, J. E., Mitsuya, H., Blam, S. B., Broder, S., and Aaronson, S. A.: Broad spectrum antiretroviral activity of 2', 3'-dideoxynucleosides. Proc. Natl. Acad. Sci. USA 84: 2469-2473, 1987.
322. Hagag, N., Lacal, J. C., Graber, M., Aaronson, S. A., and Viola, M.: Microinjection of *ras* p21 induces a rapid rise in intracellular pH. Mol. Cell. Biol. 7: 1984-1988, 1987.
323. Giese, N. A., Robbins, K. C., and Aaronson, S. A.: The role of individual cysteine residues in the structure and function of the *v-sis* gene product. Science 236: 1315-1318, 1987.
324. Albin, A., Iwamoto, Y., Kleinman, H. K., Martin, G. R., Aaronson, S. A., Kozlowski, J. M., and McEwan, R. N.: A rapid *in vitro* assay for quantitating the invasive potential of tumor cells. Cancer Res. 47: 3239-3245, 1987.
325. Kawakami, T., Sherman, L., Dahlberg, J., Gazit, A., Yaniv, A., Tronick, S. R., and Aaronson, S. A.: Nucleotide sequence analysis of equine infectious anemia virus proviral DNA. Virology 158: 300-312, 1987.
326. Finzi, E., Fleming, T., Segatto, O., Pennington, C. Y., Bringman, T. S., Derynck, R., and Aaronson, S. A.: The human transforming growth factor type α coding sequence is not a direct-acting oncogene when overexpressed in NIH 3T3 cells. Proc. Natl. Acad. Sci. USA 84: 3733-3737, 1987.
327. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., and Aaronson, S. A.: *erbB-2* is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237: 178-182, 1987.
328. Aaronson, S. A., Igarashi, H., Rao, C. D., Finzi, E., Fleming, T. P., Segatto, O., and Robbins, K. C.: Role of genes for normal growth factors in human malignancy. In Aaronson, S. A., Bishop, J. M., Sugimura, T., Terada, M., Toyoshima, K., and Vogt, P. K. (Eds.): Oncogenes and Cancer. Tokyo, Japan, Japan Scientific Societies Press and Utrecht The Netherlands, VNU Science Press BV, 1987, pp. 95-108.
329. Aaronson, S. A., Bishop, J. M., Sugimura, T., Terada, M., Toyoshima, K., and Vogt, P. K. (Eds.): Oncogenes and Cancer. Tokyo, Japan Scientific Societies Press and Utrecht The Netherlands, VNU Science Press BV, 1987, 309 pp.
330. Matyas, G. R., Aaronson, S. A., Brady, R. O., and Fishman, P. H.: Alteration of glycolipids in *ras*-transfected NIH/3T3 cells. Proc. Natl. Acad. Sci. USA 84: 6065-6068, 1987.

331. Tronick, S. R., Eva, A., Srivastava, S. K., Kraus, M. H., Yuasa, Y., and Aaronson, S. A.: The role of human *ras* proto-oncogenes in cancer. In Castellani, A. (Ed.): Epidemiology and Quantitation of Environmental Risk in Humans from Radiation and Other Agents. New York, Plenum Press, 1985, pp. 225-233.
332. Eva, A., Srivastava, S. K., Vecchio, G., Ron, D., Tronick, S. R., and Aaronson, S. A.: *dbl*: A new transforming gene isolated from a human diffuse B-cell lymphoma. In Cimino, F., Birkmayer, G. D., Klavins, J. V., Pimentel, E., and Salvatore, F. (Eds.): Human Tumor Markers. Berlin/New York, Walter De Gruyter & Co., 1987, pp. 83-92.
333. Reynolds, S. H., Stowers, S. J., Patterson, R. M., Maronpot, R. R., Aaronson, S. A., and Anderson, M. W.: Activated oncogenes in B6C3F1 mouse liver tumors: implications for risk assessment. Science 237: 1309-1316, 1987.
334. Lacal, J. C., de La Pena, P., Moscat, J., Garcia-Barreno, P., Anderson, P. S., and Aaronson, S. A.: Rapid stimulation of diacylglycerol production in *Xenopus* oocytes by microinjection of H-*ras* p21 protein. Science 238: 533-536, 1987.
335. Lacal, J. C., Fleming, T. P., Warren, B. S., Blumberg, P. M., and Aaronson, S. A.: Involvement of functional protein kinase C in the mitogenic response to the H-*ras* oncogene product. Mol. Cell. Biol. 7: 4146-4149, 1987.
336. Lacal, J. C., Moscat, J., and Aaronson, S. A.: Novel source of 1,2-diacylglycerol elevated in cells transformed by Ha-*ras* oncogene. Nature 330: 269-272, 1987.
337. Eva, A., Vecchio, G., Diamond, M., Tronick, S. R., Ron, D., Cooper, G. M., and Aaronson, S. A.: Independently activated *dbl* oncogenes exhibit similar yet distinct structural alterations. Oncogene 1: 355-360, 1987.
338. Di Fiore, P. P., Pierce, J. H., Fleming, T. P., Hazan, R., Ullrick, A., King, C. R., Schlessinger, J., and Aaronson, S. A.: Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH/3T3 cells. Cell 51: 1063-1070, 1987.
339. Eva, A., Pierce, J. H., and Aaronson, S. A.: Interactions of retroviral and cellular transforming genes with hematopoietic cells. In Peschle, C. (Ed.): Normal and Neoplastic Blood Cells: From Genes to Therapy. New York, The New York Academy of Sciences, 1987, pp. 148-170.
340. Rao, C. D., Pech, M., Robbins, K. C., and Aaronson, S. A.: The 5' untranslated sequence of the c-*sis*/PDGF-2 transcript is a potent translational inhibitor. Mol. Cell. Biol. 8: 284-292, 1988.

341. Di Fiore, P. P., Falco, J., Borrello, I., Weissman, B., and Aaronson, S. A.: The calcium signal for BALB/MK keratinocyte terminal differentiation counteracts epidermal growth factor (EGF) very early in the EGF-induced proliferative pathway. Mol. Cell. Biol. 8: 557-563, 1988.
342. Pierce, J. H., Ruggiero, M., Fleming, T. P., Di Fiore, P. P., Greenberger, J. S., Varticovski, L., Schlessinger, J., Rovera, G., and Aaronson, S. A.: Signal transduction through the EGF receptor transfected into interleukin-3-dependent hematopoietic cells. Science 239: 628-631, 1988.
343. Mitsuya, H., Dahlberg, J. E., Spigelman, Z., Matsushita, S., Jarrett, R. F., Matsukura, M., Currens, M. J., Aaronson, S. A., Reitz, M. S., McCaffrey, R. S., and Broder, S.: 2',3'-dideoxynucleosides: Broad spectrum antiretroviral activity and mechanisms of action. In Bolognesi, D. (Ed.): Human Retroviruses, Cancer, and AIDS: Approaches to Prevention and Therapy. Alan R. Liss, Inc., New York, 1988, pp. 407-421.
344. Eva, A., Vecchio, G., Rao, C. D., Tronick, S. R., and Aaronson, S. A.: The predicted *dbl* oncogene product defines a distinct class of transforming proteins. Proc. Natl. Acad. Sci. USA 85: 2061-2065, 1988.
345. Tronick, S. R. and Aaronson, S. A.: Oncogenes, growth regulation and cancer. In Adelstein, R., Klee, C. and Rodbell, M. (Eds.): Advances in Second Messenger and Phosphoprotein Research. New York, Raven Press, Ltd., 1988, pp. 201-215.
346. Kawakami, T., Kawakami, Y., Aaronson, S. A., and Robbins, K. C.: Acquisition of transforming properties by *fyn*, a normal *src*-related human gene. Proc. Natl. Acad. Sci. USA 85: 3870-3874, 1988.
347. Falco, J. P., Taylor, W. G., Di Fiore, P. P., Weissman, B. E., and Aaronson, S. A.: Interactions of growth factors and retroviral oncogenes with mitogenic signal transduction pathways of BALB/MK keratinocytes. Oncogene 2: 573-578, 1988.
348. King, C. R., Di Fiore, P. P., Pierce, J. H., Segatto, O., Kraus, M. H., and Aaronson, S. A.: Oncogenic potential of the *erbB-2* gene: frequent overexpression in human mammary adenocarcinomas and induction of transformation *in vitro*. In: Lippman, M. E. (Ed.): Growth Regulation of Cancer. Proceedings of UCLA Symposium. New York, Alan R. Liss, Inc., 1988, pp. 189-199.
349. Ron, D., Tronick, S. R., Aaronson, S. A., and Eva, A.: Molecular cloning and characterization of the human *dbl* proto-oncogene: evidence that its overexpression is sufficient to transform NIH/3T3 cells. EMBO J. 7: 2465-2473, 1988.

350. Eva, A., Srivastava, S., Vecchio, G., Ron, D., Tronick, S. R., and Aaronson, S. A.: Biochemical characterization of dbl oncogene and its product. *In* Tonini, G. P., Massimo, L., and Cornaglia-Ferraris, P., (Eds.): Oncogenes in Pediatric Tumors. London/New York, Harwood Academic Publishers, Life Science Series, 1988, vol. 4, pp. 215-231.
351. Moscat, J., Molloy, C. J., Fleming, T. P., and Aaronson, S. A.: Epidermal growth factor activates phospho-inositide turnover and protein kinase C in BALB/MK keratinocytes. Mol. Endocrinol. 9: 799-805, 1988.
352. Blam, S.B., Mitchell, R., Tischer, E., Rubin, J. S., Silva, M., Silver, S., Fiddes, J. C., Abraham, J. A., and Aaronson, S. A.: Addition of growth hormone secretion signal to basic fibroblast growth factor results in cell transformation and secretion of aberrant forms of the protein. Oncogene 3: 129-136, 1988.
353. Finzi, E., Kilkenny, A., Strickland, J. E., Balaschak, M., Bringman, T., Derynck, R., Aaronson, S. A., and Yuspa, S. H.: TGF α stimulates growth of skin papillomas by autocrine and paracrine mechanisms but does not cause neoplastic progression. Mol. Carcinogen 1: 7-12, 1988.
354. Beckmann, M. P., Betsholtz, C., Heldin, C.-H., Westermark, B., Di Fiore, P. P., Robbins, K. C., and Aaronson, S. A.: Human PDGF-A and -B chains differ in their biological properties and transforming potential. Science 241: 1346-1349, 1988.
355. Kraus, M. H., Di Fiore, P. P., Pierce, J. H., and Aaronson, S. A.: Different mechanisms are responsible for oncogene activation in human mammary neoplasia. *In* Lippman, M. E., and Dickson, B. (Eds.): Breast Cancer: Cellular and Molecular Biology. Boston, Martinus Nijhoff Publishing, 1988, pp. 49-66.
356. Robbins, K. C. and Aaronson, S. A.: The sis oncogene. *In* Reddy, E. P., Curran, T., and Skalka, A. (Eds.): The Oncogene Handbook. Elsevier, 1988, pp. 427-452.
357. Segatto, O., King, C. R., Pierce, J. H., Di Fiore, P. P., and Aaronson, S. A.: Different structural alterations upregulate *in vitro* tyrosine kinase activity and transforming potency of the *erbB-2* gene. Mol. and Cell. Biol. 8: 5570-5574, 1988.
358. Pech, M., Rao, C. D., Robbins, K. C., and Aaronson, S. A.: Functional identification of regulatory elements within the promoter region of platelet-derived growth factor 2. Mol. Cell. Biol. 9: 396-405, 1989.

359. Rubin, J. S., Osada, H., Finch, P. W., Taylor, W. G., Rudikoff, S., and Aaronson, S. A.: Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc. Natl. Acad. Sci. USA 86: 802-806, 1989.
360. Matsui, T., Heidaran, M., Miki, T., Popescu, N., La Rochelle, W. J., Kraus, M. H., Pierce, J. H., and Aaronson, S. A.: Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science 243: 800-804, 1989.
361. Kraus, M. H., Pierce, J. H., Fleming, T. P., Robbins, K. C., DiFiore, P. P., and Aaronson, S. A.: Mechanisms by which genes encoding growth factors and growth factor receptors contribute to malignant transformation. In Galeotti, T., Cittadini, A., Neri, G., and Scarpa, A. (Eds.): Membrane in Cancer Cells. New York, Annual of the New York Academy of Sciences, 1988, pp. 320-336.
362. Pech, M., Gazit, A., Arnstein, P., and Aaronson, S. A.: Generation of fibrosarcomas *in vivo* by a retrovirus that expresses the normal B chain of platelet-derived growth factor and mimics the alternative splice pattern of the *v-sis* oncogene. Proc. Natl. Acad. Sci. USA 86: 2693-2697, 1989.
363. Giese, N., May-Siroff, M., LaRochelle, W. J., Van Wyke Coelingh, K., and Aaronson, S. A.: Expression and purification of biologically active *v-sis*/PDGF-B protein using a baculovirus vector system. J. Virology 63: 3080-3086, 1989.
364. Di Marco, E., Pierce, J. H., Fleming, T. P., Kraus, M. H., Molloy, C. J., Aaronson, S. A., and Di Fiore, P. P.: Autocrine interaction between TGF α and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4:831-838, 1989.
365. Moscat, J., Fleming, T. P., Molloy, C. J., Lopez-Barahona, M., and Aaronson, S. A.: The calcium signal for BALB/MK keratinocyte terminal differentiation induces sustained alterations in phospho-inositide metabolism without detectable protein kinase C activation. J. Biol. Chem. 264: 11228-11235, 1989.
366. LaRochelle, W. J., Robbins, K. C., and Aaronson, S. A.: Immunochemical localization of the epitope for a monoclonal antibody that neutralizes human platelet-derived growth factor mitogenic activity. Mol. Cell. Biol. 9: 3538-3542, 1989.
367. Finch, P. W., Rubin, J. S., Miki, T., Ron, D., and Aaronson, S. A.: Human KGF is FGF-related with properties of a paracrine effector of epithelial cell. Science 245: 752-755, 1989.

368. Ron, D., Graziani, G., Aaronson, S. A., and Eva, A.: The N-terminal region of proto-*dbl* down regulates its transforming activity. Oncogene 4: 1067-1072, 1989.
369. Aaronson, S. A., Falco, J. P., Taylor, W. G., Cech, A. C., Marchese, C., Finch, P. W., Rubin, J. S., Weissman, B. E., and Di Fiore, P.P.: Pathways in which growth factors and oncogenes interact in epithelial cell mitogenic signal transduction. Ann. NY Acad. Sci. 567: 122-129, 1989.
370. Kraus, M. H., Di Fiore, P. P., Pierce, J. H., Robbins, K. C., and Aaronson, S. A.: Overexpression of proto-oncogenes encoding growth factor or growth factor receptor proteins in malignancy. In Furth, M., and Greaves, M. (Eds.): Cancer Cells 7/Molecular Diagnostics of Human Cancer. New York, Cold Spring Harbor Laboratory, 1989, pp. 303-309.
371. Fleming, T. P., Matsui, T., Molloy, C. J., Robbins, K. C., and Aaronson, S. A.: Autocrine mechanism for v-*sis* transformation requires cell surface localization of internally activated growth factor receptors. Proc. Natl. Acad. Sci. USA 86: 8063-8067, 1989.
372. Matsui, T., Pierce, J. H., Fleming, T. P., Greenberger, J. S., LaRochelle, W. J., Ruggiero, M., and Aaronson, S. A.: Independent expression of human α or β platelet-derived growth factor receptor cDNAs in a naive hematopoietic cell leads to functional coupling with mitogenic and chemotactic signaling pathways. Proc. Natl. Acad. Sci. USA 86: 8314-8318, 1989.
373. Miki, T., Matsui, T., Heidaran, M. A., and Aaronson, S. A.: An efficient directional cloning system to construct cDNA libraries containing full-length inserts at high frequency. Gene 83: 137-146, 1989.
374. Molloy, C. J., Bottaro, D. P., Fleming, T. P., Marshall, M. S., Gibbs, J. B., and Aaronson, S. A.: PDGF induction of tyrosine phosphorylation of GTPase activating protein. Nature 342: 711-714, 1989.
375. Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., and Aaronson, S. A.: Isolation and characterization of *erbB-3*, a third member of the *erbB*/epidermal growth factor receptor family: Evidence for over-expression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA 86: 9193-9197, 1989.
376. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Fleming, T. P., Robbins, K. C., and Aaronson, S. A.: The role of growth factors and growth factor receptors in neoplastic cell transformation. In Sorenson, G.D. (Ed.): Lung Cancer, International Conference on Hormones, Growth Factors and Oncogenes in Pulmonary Carcinoma. Elsevier Science Publishers, 1988, pp. 135-154.

377. Fleming, T. P., Pech, M. W., Di Marco, E., Di Fiore, P. P., Falco, J. P., and Aaronson, S. A. Gene encoding growth factors as oncogenes. *In* Cavenee, W., Hastie, N. and Stanbridge, E. (Eds.). Current Communications in Molecular Biology. New York, Cold Spring Harbor Press, 1989, pp. 203-209.
378. Molloy, C. J., Fleming, T. P., Bottaro, D. P., and Aaronson, S. A.: PDGF signaling pathways in malignancy. *In* Papas, T.S. (Ed.): Oncogenesis: Oncogenes in Signal Transduction and Cell Proliferation. Houston, Gulf Publishing, 1990, pp. 13-23.
379. Di Fiore, P. P., Segatto, O., Taylor, W. G., Aaronson, S. A., and Pierce, J. H.: EGF-receptor and *erbB*-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science 248: 79-83, 1990.
380. Di Fiore, P. P., Segatto, O., Lonardo, F., Fazioli, F., Pierce, J. H., and Aaronson, S. A.: The carboxy-terminal domains of *erbB*-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. Mol. Cell. Biol. 10: 2749-2756, 1990.
381. Melchiori, A., Carlone, S., Allavena, G., Aresu, O., Parodi, S., Aaronson, S. A., and Albini, A.: Invasiveness and chemotactic activity of oncogene transformed NIH/3T3 cell. Anticancer Research 10: 37-44, 1990.
382. LaRochelle, W. J., Giese, N., May-Siroff, M., Robbins, K. C., and Aaronson, S. A.: Molecular localization of the transforming and secretory properties of PDGF A and PDGF B. Science 248: 1541-1544, 1990.
383. Di Marco, E., Pierce, J. H., Aaronson, S. A., and Di Fiore, P. P.: Mechanisms by which EGF receptor and TGF α contribute to malignant transformation. Nat. Immun. Cell Growth Regul. 9:209-221, 1990.
384. Bottaro, D. P., Rubin, J. S., Ron, D., Finch, P. W., Florio, C., and Aaronson, S. A.: Characterization of the receptor for keratinocyte growth factor: evidence for multiple fibroblast growth factor receptors. J. Biol. Chem. 265: 12767-12770, 1990.
385. Miki, T., Matsui, T., Heidaran, M. A., and Aaronson, S. A.: Automatic directional cloning: an efficient method to construct eukaryotic expression cDNA libraries. *In* Alitalo, K.K., Huhtala, M.-L., Knowles, J. and Vaheri, A. (Eds.). Proceedings of the International Symposium on Recombinant Systems in Protein Expression. Amsterdam, Elsevier Science Publishers BV, 1990, pp. 125-136.
386. Aaronson, S. A., and Pierce, J. H.: Molecular mimicry of growth factors by products of tumor viruses. Cancer Cells 2: 212-214, 1990.

387. Marchese, C., Rubin, J. S., Ron, D., Faggioni, A., Torrisi, M. R., Messina, A., Frati, L. and Aaronson, S. A.: Human keratinocyte growth factor activity on proliferation and differentiation of human keratinocytes: differentiation response distinguishes KGF from EGF family. J. Cell. Physiol. 144: 326-332, 1990.
388. Heidaran, M. A., Fleming, T. P., Bottaro, D. P., Bell, G. I., Di Fiore, P. P., and Aaronson, S. A.: Transformation of NIH/3T3 fibroblasts by an expression vector for the human epidermal growth factor precursor. Oncogene 5: 1265-1270, 1990.
389. Kruh, G. D., Perego, R., Miki, T., and Aaronson, S. A.: The complete coding sequence of *arg* defines the Abelson subfamily of cytoplasmic tyrosine kinases. Proc. Natl. Acad. Sci. USA 87: 5802-5806, 1990.
390. Pierce, J. H., Di Marco, E., Cox, G. W., Lombardi, D., Ruggiero, M., Varesio, L., Wang, L. M., Choudhury, G. G., Sakaguchi, A. Y., Di Fiore, P. P., and Aaronson, S. A.: Macrophage-colony-stimulating factor (CSF-1) induces proliferation, chemotaxis and reversible monocytic differentiation in myeloid progenitor cells transfected with the human *c-fms*/CSF-1 receptor cDNA. Proc. Natl. Acad. Sci. USA 87: 5613-5617, 1990.
391. Giese, N., LaRoche, W. J., May-Siroff, M., Robbins, K. C., and Aaronson, S. A.: A small *v-sis*/platelet-derived growth factor (PDGF) B- protein domain in which subtle conformational changes abrogate PDGF receptor interaction and transforming activity. Mol. Cell. Biol. 10: 5496-5501, 1990.
392. McKinnon, R. D., Matsui, T., Dubois-Dalcq, M., and Aaronson, S. A.: bFGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 5: 603-614, 1990.
393. Crescenzi, M., Fleming, T. P., Lassar, A. B., Weintraub, H., and Aaronson, S. A.: MyoD induces growth arrest independent of differentiation in normal and transformed cells. Proc. Natl. Acad. Sci. USA 87: 8442-8446, 1990.
394. Heidaran, M. A., Pierce, J. H., Jensen, R. A., Matsui, T., and Aaronson, S. A.: Chimeric α - and β -platelet-derived growth factor (PDGF) receptors define three immunoglobulin-like domains of the α -PDGF receptor that determine PDGF-AA binding specificity. J. Biol. Chem. 265: 18741-18744, 1990.
395. Aaronson, S. A., Rubin, J. S., Finch, P. W., Wong, J., Marchese, C., Falco, J., Taylor, W. G., and Kraus, M. H.: Growth factor regulated pathways in epithelial cell proliferation. Am. Rev. Respir. Dis. 142: S7-S10, 1990.

396. Lonardo, F., Di Marco, E., King, C. R., Pierce, J. H., Segatto, O., Aaronson, S. A., and Di Fiore, P. P. The normal *erbB-2* product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol. 2: 992-1003, 1990.
397. Rubin, J. S., Chan, A. M.-L., Bottaro, D. P., Burgess, W. H., Taylor, W. G., Cech, A. C., Hirschfield, D. W., Wong, J., Miki, T., Finch, P. W., and Aaronson, S. A.: A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc. Natl. Acad. Sci. USA 88: 415-419, 1991.
398. Heidaran, M. A., Pierce, J. H., Lombardi, D., Ruggiero, M., Gutkind, J. S., Matsui, T., and Aaronson, S. A.: Deletion or substitution within the α platelet-derived growth factor receptor kinase insert domain: effects on functional coupling with intracellular signaling pathways. Mol. Cell. Biol. 11: 134-142, 1991.
399. Miki, T., Fleming, T. P., Bottaro, D. P., Rubin, J. S., Ron, D., and Aaronson, S. A.: Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop. Science 251: 72-75, 1991.
400. LaRochelle, W. J., Giese, N., May-Siroff, M., Robbins, K. C., and Aaronson, S. A.: Chimeric molecules map and dissociate the potent transforming and secretory properties of PDGF A and PDGF B. J. Cell Sci. Suppl. 13: 31-42, 1990.
401. Bottaro, D. P., Rubin, J., Faletto, D. L., Chan, A. M.-L., Kmiecik, T. E., Vande Woude, G. F., and Aaronson, S. A.: Identification of the hepatocyte growth factor receptor is the *c-met* proto-oncogene product. Science 251: 802-804, 1991.
402. Molloy, C. J., Fleming, T. P., Bottaro, D. P., Cuadrado, A., Pangelinan, M. J., and Aaronson, S. A.: Oncogenes and signal transduction in malignancy. In Brinkley, W., Lechner, J. and Harris, C. (Eds.): Current Communications in Molecular Biology: Cellular and Molecular Aspects of Fiber Carcinogenesis. New York, Cold Spring Harbor Laboratory Press, 1991, pp. 67-81.
403. LaRochelle, W. J., Giese, N., Robbins, K. C., and Aaronson, S. A.: Variant PDGF ligands and receptors-structure/function relationship. News in Physiol. Sci. 6: 56-60, 1991.
404. Ron, D., Zannini, M., Lewis, M., Wichner, R. B., Hunt, L. T., Graziani, G., Tronick, S. R., Aaronson, S. A., and Eva, A.: A region of proto-*dbl* essential for its transforming activity shows sequence similarity to a yeast cell cycle gene, CDC24 and the human breakpoint cluster gene, *bcr*. New Biol. 3: 372-379, 1991.
405. Aaronson, S. A., and Tronick, S.R.: Growth factor signalling pathways and their alterations in human tumors. FORUM 1.1: 14-35, 1991.

406. Smith, A., Seldin, M.F., Martinez, L., Watson, M.L., Choudhury, G.G., Lalley, P.A., Pierce, J., Aaronson, S.A., Barker, J., Naylor, S.L., and Sakaguchi, A.Y.: Mouse platelet-derived growth factor receptor a gene is deleted in W19H and patch mutations on chromosome 5. Proc. Natl. Acad. Sci. USA 88: 4811-4815, 1991.
407. LaRochelle, W. J., May-Siroff, M., Robbins, K. C., and Aaronson, S. A.: A novel mechanism regulating growth factor association with the cell surface: identification of a PDGF retention domain. Genes Dev. 5: 1191-1199, 1991.
408. Miki, T., Fleming, T. P., Crescenzi, M., Molloy, C. J., Blam, S. B., Reynolds, S. H., and Aaronson, S. A.: Development of a highly efficient expression cDNA cloning system: Application to oncogene isolation. Proc. Natl. Acad. Sci. USA 88: 5167-5171, 1991.
409. Yu, J-C., Heidaran, M. A., Pierce, J. H., Gutkind, J. S., Lombardi, D., Ruggiero, M., and Aaronson, S. A.: Tyrosine mutations within the α platelet-derived growth factor receptor kinase insert domain abrogate receptor-associated phosphatidylinositol-3 kinase activity without affecting mitogenic or chemotactic signal transduction. Mol. Cell. Biol. 11: 3780-3785, 1991.
410. Takahashi, R., Hashimoto, T., Xu, H-J., Hu, S-X., Matsui, T., Bigo-Marshall, H., Aaronson, S. A., and Benedict, W. F.: The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. Proc. Natl. Acad. Sci. USA. 88: 5257-5261, 1991.
411. Kraus, M. H. and Aaronson, S. A.: Detection and isolation of novel protein-tyrosine kinase genes employing reduced stringency hybridization. In Hunter, T. and Sefton, B. M. (Eds.). Methods in Enzymology "Protein Phosphorylation." San Diego, Academic Press, Inc., 1991, pp. 546-556.
412. Pierce, J. H., Arnstein, P., DiMarco, E., Artrip, J., Kraus, M. H., Lonardo, F., Di Fiore, P. P., and Aaronson, S. A.: Oncogenic potential of *erbB-2* in human mammary epithelial cells. Oncogene 6: 1189-1194, 1991.
413. Heidaran, M.A., Pierce, J.H., Yu, J-C., Lombardi, D., Artrip J.E., Fleming, T.P., Thomason, A., and Aaronson, S.A.: Role of $\alpha\beta$ receptor heterodimer formation in β platelet-derived growth factor (PDGF) receptor activation by PDGF-AB. J. Biol. Chem. 266: 20232-20237, 1991.
414. Aaronson, S.A.: Growth factors and cancer. Science 254: 1146-1153, 1991.

415. Chan, A., Rubin, J., Bottaro, D., Hirschfield, D., Chedid, M. and Aaronson, S. A.: Identification of a competitive HGF antagonist encoded by an alternative transcript. Science 254: 1382-1385, 1991.
416. Tronick, S. R. and Aaronson, S. A.: Oncogenes. In Cossman, J. (Ed.). Mol. Genetics in Cancer Diagnosis. Amsterdam, Elsevier Science Publishers BV, 1991, pp. 29-41.
417. Aaronson, S. A. and Tronick, S. R.: Constitutive activation of growth factor signalling pathways in cancer cells. In Broder, S. (Ed.): Molecular Foundations of Oncology. Hanover, Sheridan Press, 1991, pp. 41-53.
418. Hart, M.J., Eva, A., Evans, T., Aaronson, S.A., and Cerione, R.A.: The *dbl* oncogene product catalyzes guanine nucleotide exchange on the CDC42Hs protein. Nature. 354: 311-314, 1991.
419. Di Fiore, P. P., Segatto, O., and Aaronson, S. A.: Cloning, expression and biological effects of the *erbB2/neu* gene in mammalian cells. Methods in Enzymology 198: 272-277, 1991.
420. Aaronson, S. A., Bottaro, D. P., Miki, T., Ron, D., Finch, P. W., Fleming, T. P., Ahn, J., Taylor, W. G., and Rubin, J. S.: Keratinocyte growth factor, a fibroblast growth factor family member with unusual target cell specificity. Ann. NY Acad. Sci. 638: 62-77, 1991.
421. Miki, T., Fleming, T.P., and Aaronson, Stuart A.: Expression cDNA cloning of growth control genes. In Verna, R. and Nishizuka, Y. (Eds.); Biotechnology of Cell Regulation. New York, Raven Press, 1992, pp. 193-203.
422. Miki, T., Bottaro, D.P., Fleming, T.P., Smith, C., Burgess, W.H., Chan, A. M.-L., and Aaronson, S.A.: Determination of ligand-binding specificity by alternative splicing: Two distinct growth factor receptors encoded by a single gene. Proc. Natl. Acad. Sci. USA 89: 246-250, 1992.
423. Heidaran, M.A., Yu, J.-C., Jensen, R.E., Pierce, J.H. and Aaronson, S.A.: A deletion in the extracellular domain of the α platelet-derived growth factor (PDGF) receptor differentially impairs PDGF-AA and PDGF-BB binding affinities. J. Biol. Chem. 267: 2884-2887, 1992.
424. Miki, T., Bottaro, D.P., Fleming, T.P., Smith, C.L., Rubin, J.S., Chan, A. M.-L., and Aaronson, S.A. KGF receptor: transforming potential on fibroblasts and epithelial cell-specific expression by alternative splicing. In Papa, S., Azzi, A. and Trager, J.M. (Eds.): Molecular and Cell Biology Updates. Basel, Switzerland, Birkhauser Verlag, 1992, pp. 289-300.

425. Fleming, T. P., Matsui, T., Heidaran, M.A., Molloy, C. J., Artrip, J., and Aaronson, S. A.: Demonstration of an activated platelet-derived growth factor autocrine pathway and its role in human tumor cell proliferation *in vitro*. Oncogene 7: 1355-1359, 1992.
426. Fleming, T. P., Saxena, A., Clark, W. C., Robertson, J. T., Oldfield, E. H., Aaronson, S. A. and Ali, I. U.: Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 52: 4550-4553, 1992.
427. Molloy, C. J., Fleming, T. P., Bottaro, D. P., Cuadrado, A., and Aaronson, S. A.: Platelet-derived growth factor stimulation of GTPase-activating protein tyrosine phosphorylation in control and c-H^{ras}-expressing NIH/3T3 cells correlates with p21^{ras} activation. Mol. Cell. Biol. 12: 3903-3909, 1992.
428. LaRochelle, W. J., Pierce, J. H., May-Siroff, M., Giese, N., and Aaronson, S. A.: Five PDGF B amino acid substitutions convert PDGF A to a PDGF B-like transforming molecule. J. Biol. Chem. 267: 17074-17077, 1992.
429. Kelley, M. J., Pech, M., Seuanez, H. N., Rubin, J. S., O'Brien, S. J., and Aaronson, S. A.: Emergence of the keratinocyte growth factor multigene family during the great ape radiation. Proc. Natl. Acad. Sci. USA 89: 9287-9291, 1992.
430. Fleming, T. P., Matsui, T., and Aaronson, S. A.: Platelet-derived growth factor (PDGF) receptor activation in cell transformation and human malignancy. Exp. Gerontol. 27: 523-527, 1992.
431. Rong, S., Bodescot, M., Blair, D., Dunn, J., Nakamura, T., Mizuno, K., Park, M., Chan, A., Aaronson, S., and Vande Woude, G. F.: Tumorigenicity of the *met* protooncogene and the gene hepatocyte growth factor. Mol. Cell. Biol. 12: 5152-5158, 1992.
432. LaRochelle, W.J., Fleming, T., and Aaronson, S.A.: PDGF in cell transformation. In Westermarck, B. and Sorg, C. (Eds.): Biology of Platelet-Derived Growth Factor. Basel, Karger Medical and Scientific Publishers, 1993, pp. 129-145.
433. Ishibashi, T., Bottaro, D. P., Chan, A., Miki, T., and Aaronson, S.A.: Expression cloning of a novel human dual-specificity phosphatase. Proc. Natl. Acad. Sci. USA 89: 12170-12174, 1992.
434. Chan, A., Rubin, J., Bottaro, D., Hirschfield, D., Chedid, M., and Aaronson, S. A.: Isoforms of human HGF and their biological activities. In Goldberg, I. D. and

Rosen, E. M. (Eds.): Hepatocyte Growth Factor-Scatter Factor and the c-MET Receptor. Birkhauser Verlag, 1993, pp. 67-79.

435. Chan, A. M.-L., Fleming, T. P., McGovern E. S., Chedid, M., Miki, T., and Aaronson, S. A.: Expression cDNA cloning of a transforming gene encoding the wild-type $G\alpha_{12}$ gene product. Mol. Cell. Biol. 13: 762-768, 1993.
436. Ron, D., Bottaro, D. P., Finch, P. W., Morris, D., Rubin, J. S., and Aaronson, S.A.: Expression of biologically active recombinant keratinocyte growth factor: structure/function analysis of amino-terminal truncation mutants. J. Biol. Chem. 268: 2984-2988, 1993.
437. Aaronson, S. A. and Tronick, S. R.: Growth factors. In Holland, J. F., Frei, Ill, E., Bast, Jr., R. C., Kufe, D. W., Morton, D. L. and Weichselbaum, R. R. (Eds.): Cancer Medicine, 3rd Edition. Philadelphia, Lea & Febiger, 1993, pp. 33-48.
438. Kraus, M. H., Fedi, P., Starks, V., Muraro, R., and Aaronson, S. A.: Demonstration of ligand-dependent signaling by the human *erbB-3* tyrosine kinase and its constitutive activation in human breast tumor cells. Proc. Natl. Acad. Sci. USA 90: 2900-2904, 1993.
439. Chan, A. M.-L., Chedid, M., McGovern, E. S., Popescu, N. C., Miki, T., and Aaronson, S. A.: Expression cDNA cloning of a serine kinase transforming gene. Oncogene 8: 1329-33, 1993.
440. Wang, L.-M., Keegan, A. D., Li, W., Lienhard, G. E., Pacini, S., Gutkind, J. S., Myers, Jr., M. G., Sun, X-J., White, M. F., Aaronson, S. A., Paul, W. E., and Pierce, J. H.: Common elements in IL-4 and insulin signaling pathways in factor-dependent hematopoietic cells. Proc. Natl. Acad. Sci. USA 90: 4032-4036, 1993.
441. Bottaro, D. P., Fortney, E., Rubin, J. S., and Aaronson, S. A.: A keratinocyte growth factor receptor-derived peptide antagonist identifies part of the ligand binding site. J. Biol. Chem. 268: 9180-9183, 1993.
442. Miki, T. and Aaronson, S. A.: cDNA cloning method using stable expression in mammalian cells. In Adolph, K.W. (Ed.): Methods in Molecular Genetics, Vol. 1. Orlando, FL, Academic Press, Inc., 1993, pp. 3-22.
443. Heidaran, M. A., Beeler, J. F., Yu, J.-C., Ishibashi, T., LaRochelle, W. J., Pierce, J. H., and Aaronson, S.A.: Differences in substrate specificities of α and β platelet-derived growth factor (PDGF) receptors. J. Biol. Chem. 268: 9287-9295, 1993.
444. LaRochelle, W. J., Jensen, R. A., Heidaran, M. A., May-Siroff, M., Wang, L.-M., Aaronson, S. A., and Pierce, J. H.: Inhibition of platelet-derived growth factor

autocrine growth stimulation by a monoclonal antibody to the human α platelet-derived growth factor receptor. Cell Growth Differ. 4: 547-553, 1993.

445. Cuadrado, A., Bruder, J. T., Heidaran, M. A., App, H., Rapp, U. R., and Aaronson, S. A.: H-ras and raf-1 cooperate in transformation of NIH/3T3 fibroblasts. Oncogene 8: 2443-2448, 1993.
446. Aaronson, S. A.: Influences of growth factors and their signaling pathways in malignancy. The Harvey Lectures, Series 87. New York, NY, Wiley-Liss, 1993, pp. 17-34.
447. Chan, M.-L. and Aaronson, S. A.: An efficient expression cDNA cloning approach to screen human tumors for oncogenes. In Cittadini, A. (Ed.): Molecular Oncology and Clinical Applications. Basel, Switzerland, Birkhauser Verlag, 1993, pp. 111-122.
448. Panos, R. J., Rubin, J. S., Aaronson, S. A., and Mason, R. J.: Keratinocyte growth factor and hepatocyte growth factor/scatter factor are heparin-binding growth factors for alveolar type II cells in fibroblast conditioned medium. J. Clin. Invest. 92: 969-977, 1993.
449. Staiano-Coico, L., Krueger, J. G., Rubin, J. S., D'limi, S., Vallat, V. P., Valentino, L., Fahey III, T., Hawes, A., Kingston, G., Madden, M. R., Mathwich, M., Gottlieb, A., and Aaronson, S.A.: Human keratinocyte growth factor effects in a porcine model of epidermal wound healing. J. Exp. Med. 178: 865-878, 1993.
450. Suzuki, M., Itoh, T., Osada, H., Rubin, J. S., Aaronson, S. A., Suzuki, T., Koga, N., Saito, T., and Mitsui, Y.: Spleen-derived growth factor, SDGF-3, is identified as keratinocyte growth factor (KGF). FEBS Lett. 328: 17-20, 1993.
451. May, M., Aaronson, S. A., and LaRochelle, W. J.: Platelet-derived growth factor AB heterodimer interchain interactions influence on secretion as well as receptor binding and activation. Biochemistry 32: 11734-11740, 1993.
452. Wang, L-M., Myers Jr., M. G., Sun, X-J., Aaronson, S. A., White, M., and Pierce, J. H.: Expression of IRS-1 restores insulin- and IL-4 mediated mitogenesis in hematopoietic cells. Science. 261: 1591-1594, 1993.
453. Miki, T., and Aaronson, S. A.: Use of λ -plasmid composite vectors for expression cDNA cloning. In Hardy, K. G. (Ed.): Plasmids: A Practical Approach. Geneva, Switzerland, Oxford University Press, 1993, pp. 177-196.
454. Aaronson, S. A., Miki, T., Meyers, K., and Chan, A.: Growth factors and malignant transformation. In Zappia, V., Salvatore, M. and Della Ragione, F.

(Eds.): Advances in Nutrition and Cancer. New York, Plenum Press, 1993, pp. 7-22.

455. Hart, M. J., Eva, A., Zangrilli, D., Aaronson, S. A., Evans, T., Cerione, R. A., and Zheng, Y.: Cellular transformation and guanine nucleotide exchange activity are catalyzed by a common domain on the *dbl* oncogene product. J. Biol. Chem. 269:62-65, 1994.
456. Beeler, J.F., LaRochelle, W.J., Chedid, M., Tronick, S.R. and Aaronson, S.A.: Prokaryotic expression cloning of a novel human tyrosine kinase. Mol. Cell. Biol. 14:982-988, 1994.
457. Rubin, J.S., Bottaro, D.P., and Aaronson, S.A.: Hepatocyte growth factor/scatter factor and its receptor, the *c-met* proto-oncogene product. Biochim. Biophys. Acta. 1155:357-371, 1994.
458. Cheon, H-G., LaRochelle, W. J., Bottaro, D. P., Burgess, W. H., and Aaronson, S.A.: High affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains. Proc. Natl. Acad. Sci. USA. 91:989-993, 1994.
459. Strain, A. J., McGuinness, G., Rubin, J. S., and Aaronson, S. A.: Keratinocyte growth factor and fibroblast growth factor action on DNA synthesis in rat and human hepatocytes: modulation by heparin. Exp. Cell. Res. 210:253-259, 1994.
460. Alarid, E. T., Rubin, J. S., Young, P., Chedid, M., Ron, D., Aaronson, S. A., and Cunha, G. R.: Keratinocyte growth factor functions in epithelial induction during seminal vesicle development. Proc. Natl. Acad. Sci. USA. 91:1074-1078, 1994.
461. Chedid, M., Rubin, J. S., Csaky, K. G., and Aaronson, S. A.: Regulation of keratinocyte growth factor gene expression by interleukin 1. J. Biol. Chem. 269:10753-10757, 1994.
462. Koji, T., Chedid, M., Rubin, J.S., Slayden, Ov D., Csaky, K.G., Aaronson, S.A., and Brenner, R.M.: Progesterone dependent expression of keratinocyte growth factor (KGF) mRNA in stromal cells of the primate endometrium: KGF as a prostomedin. J. Cell Biol. 125:393-401, 1994.
463. Chan, A.M.L., Miki, T., Meyers, K.A., and Aaronson, S.A.: A New Human Oncogene of the *ras* superfamily unmasked by expression cDNA Cloning. Proc. Natl. Acad. Sci. USA. 91:16, 7558-7562, 1994.

464. Kruh, G.D., Chan, A.M., Meyers, K.A., Gaughan, K., Miki, T., and Aaronson, S. A.: Expression cDNA Library Transfer Establishes *mrp* as a Multidrug Resistance Gene. Cancer Research. 54:7, 1649-1652, 1994.
465. Saez, R., Chan, A.M.-L., Miki, T., and Aaronson, S.A.: Oncogenic activation of human R-ras by point mutations analogous to those of prototype H-ras oncogenes. Oncogene. 9: 2977-2982, 1994.
466. Cunha, G.R., Foster, B.A., Donjacour, A.A., Rubin, J.S., Sugimura, Y., Finch, P.W., Brody, J.R., and Aaronson, S.A.: Keratinocyte growth factor: a mediator of mesenchymal-epithelial interactions in the development of androgen target organs. In Motta, M., and Serio, L. (Eds.): Sex hormones and antihormones in endocrine dependent pathology: Basic and clinical aspects. New York, Elsevier Science B.V., 1994, pp. 45-57.
467. Ishibashi, T., Bottaro, D.P., Michieli, P., Kelley, C.A., and Aaronson, S.A.: A novel dual-specificity phosphatase induced by serum stimulation and heat shock. J. Biol. Chem. 269:47, 29897-29902, 1994.
468. Goldstein, D.J., Li, W., Wang, L.-M., Heidarman, M.A., Shinn, R., Aaronson, S.A., Schlegel, R., and Pierce, J.H.: The BPV-1 E5 transforming protein cooperates with the β but not the α PDGF receptor to induce transformation of a murine hematopoietic progenitor cell line. J. Virol. 7: 4432-4441, 1994.
469. Bottaro, D. P., Chan, A. M.-L., Rubin, J. S., Gak, E., Fortney, E., Schindler, J., Chedid, M. and Aaronson, S. A.: The HGF-c-*met* signaling pathway. In Kitagawa, Y., & Tartakoff, A. M. (Ed.): Advance in Biochemistry and Biology of Cells. Vol. 3, pp 1-14, JAI Press, Inc., Greenwich, CT., 1994
470. Tronick, S.R. and Aaronson, S.A.: Growth factors and signal transduction. In Mendelsohn, J., Howley, P., Liotta, L. and Israel, M. (Eds.): The Molecular Basis of Cancer. Philadelphia, W. B. Saunders Co., 1995, pp. 117-140.
471. La Rochelle, W.J., Dirsch, O.R., Cheon H.G., May, M., Marchese, C., Pierce, J.H. and Aaronson, S.A.: Specific receptor immunodetection by a functional KGF-immunoglobulin chimera. Journal of Cell Biology. 129:2, 357-366, 1995.
472. Lorenzi, M.V., Long, J.E., Miki, T. and Aaronson, S.A.: Expression cloning, developmental expression and chromosomal localization of fibroblast growth factor-8. Oncogene. 10: 2051-2055, 1995.
473. Aaronson, S.A.: Lung Cancer: Emerging therapeutic approaches based on molecular genetics. The Mount Sinai Journal of Medicine. 62:3, 204-205, 1995.

474. Alimandi, M., Romano, A., Curia, M.C., Muraro, R., Fedi, P., Aaronson, S.A., Di Fiore, P.P. and Kraus, M.H.: Cooperative signaling of *erbB-3* and *erbB-2* in neoplastic transformation and human mammary tumors. Oncogene. 10:1813-1821, 1995.
475. Aroca, P., Bottaro, D.P., Ishibashi, T., Aaronson, S.A. and Santos, E.: Human dual specificity phosphatase VHR activates MPF and triggers meiotic maturation in *Xenopus* oocytes. J. Biol. Chem. 270:23, 14229-14234, 1995.
476. Miki, T. and Aaronson, S.A.: Isolation of oncogenes by expression cDNA cloning. In Peter K. Vogt and Inder M. Verma, (Eds.): Methods in Enzymology: Oncogene Techniques. San Diego, California, Academic Press, 1995, pp. 196-206.
477. Huang, Y., Saez, R., Chao, L., Santos, E., Aaronson, S.A. and Chan, A.M.-L.: A novel insertional mutation in the *TC21* gene activates its transforming activity in a human leiomyosarcoma cell line. Oncogene 11:1255-1260, 1995.
478. Cunha, G.R., Sugimura, Y., Foster, B., Rubin, J.S. and Aaronson, S.A.: The role of growth factors in the development and growth of the prostate and seminal vesicle. Biomed. Pharmacotherapy 48:S9-S19, 1995.
479. Marchese, C., Chedid, M., Dirsch, O.R., Csaky, K.G., Santanelli, F., Latini, C., LaRochelle, W.J., Torrisi, M.R. and Aaronson, S.A.: Modulation of keratinocyte growth factor and its receptor in reepithelializing human skin. J. Exp. Med. 182:1369-1376, 1995.
480. Breuninger, L.M., Paul, S., Gaughan, K., Miki, T., Chan, A., Aaronson, S.A. and Kruh, G.D.: Expression of MRP in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Research. 55:22, 5342-5347, 1995.
481. Cioce, V., Csaky, K.G., Chan, A., Bottaro, D.P., Taylor, W.G., Jensen, R., Aaronson, S.A. and Rubin, J.S.: Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity. The Journal of Biological Chemistry. 271:22, 13110-13115, 1996.
482. Tachibana, M., Takeda, K., Nobukuni, Y., Urabe, K., Meyers, K., Aaronson, S. A., and Miki, T.: Ectopic expression of *MITF*, a gene for Waardenberg syndrome type 2, converts fibroblasts to cells with melanocytic morphology and melanogenic markers. Nature Genetics. 14:50-54, 1996
483. da Medina, S.G.D., Chopin, D., Marjon, A.E., Delougee, A., LaRochelle, W.J., Hoznek, A., Abbou, C., and Aaronson, S.A., Thiery, J.P., Radvanyi, F.:

Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene. 14:1-8, 1997

484. Sugimura, Y., Foster, B.A., Hom, Y.K., Lipschutz, J.H., Rubin, J.S., Finch, P.W., Aaronson, S.A., Hayashi, N., Kawamura, J., and Cunha, G.R.: Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate. Int. J. Dev. Biol. 40:1-11, 1996.
485. Fedi, P., Tronick, S. and Aaronson, S.A.: Growth factors. In "Cancer Medicine" 4th Edition. Edited by Holland, J. F., et al. Baltimore, Williams & Wilkins, 1996.
486. Takayama, H., LaRochelle, W.J., Sharp, R., Otsuka, T, Kriebel, P., Anver, M., Aaronson, S.A., and Merlino, G.: Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc. Natl. Acad. Sci. USA 94:701-706, 1997
487. Shin, D-Y., Ishibashi, T., Choi, T.S., Chung, E., Chung, I.Y., Aaronson, S.A., and Bottaro, D.P.: A novel human ERK phosphatase regulates H-ras and v-raf signal transduction. Oncogene. 14:2633-2639, 1997
488. Kirschenbaum, A., Wang, J-P., Ren, M., Schiff, J.D., Aaronson, S.A., Droller, M.J., Ferrara, N., Holland, J.F., and Levine, A.C.: Inhibition of vascular endothelial cell growth factor suppresses the *in vivo* growth of tumors produced by the co-inoculation of LNCAP human prostate cancer cells and human fetal fibroblasts. Urologic Oncology 3(1): 3-10, 1998.
489. Finch, P.W., He, X., Kelley, M.J., Uren, A., Schaudies, P., Popescu, N.C., Rudikoff, S., Aaronson, S.A., Varmus, H.E., and Rubin, J.S.: Purification and Molecular Cloning of a Secreted, Frizzled-Related Antagonist of Wnt Action. Proc. Natl. Acad. Sci. USA 94:6770-6775, 1997.
490. Sugrue, M., Shin, D.Y., Lee, S.W., and Aaronson, S.A.: Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Natl. Acad. Sci. USA 94:9648-9653, 1997
491. Zimonjic, D.B., Kelley, M.J., Rubin, J.S., Aaronson, S.A., and Popescu, N.C.: FISH analysis of keratinocyte growth factor (KGF) gene amplification and dispersion in evolution of great apes and humans. Proc. Natl. Acad. Sci. USA 94:11461-11465, 1997
492. Ouchi, T., Monteiro, A.N.A., August, A., Aaronson, S.A., Hanafusa, H.: BRCA1 regulates p53-dependent gene expression. Proc. Natl. Acad. Sci. USA 95:2302-2306, 1998.

493. Montesano, R., Soriano, J.V., Malinda, K.M., Ponce, M.L., Bafico, A., Kleinman, H.K., Bottaro, D.P., Aaronson, S.A.: Differential Effects of Hepatocyte Growth Factor Isoforms on Epithelial and Endothelial Tubulogenesis. Cell Growth and Differentiation 9:355-365, 1998
494. Igarashi, M., Finch, P.W., and Aaronson, S.A.: Characterization of recombinant human FGF-10 reveals functional similarities with keratinocyte growth factor (FGF-7). J. Biol. Chem 273(18):13230-13235, 1998
495. Bafico, A., Gazit, A., Wu-Morgan, S.S., Yaniv, A., and Aaronson, S.A.: Characterization of Wnt-1 and Wnt-2 induced growth alterations and signalling pathways in NIH3T3 fibroblasts. Oncogene. 15:2819-2825 , 1998.
496. Levin, A.C., Liu, X-H., Ren, M., Wang, J-P., Schiff, J.D., Diamond, E.J., Finch, P.W., Aaronson, S.A., Kirschenbaum, K.: Androgenic effects on prostate specific antigen secretion by human fetal prostate are mediated by keratinocyte growth factor. Molec. Urol. 2(2):65-71, 1998
497. Kurdistan, S.K., Arizti, P., Sugrue, M.M., Aaronson, S.A., and Lee, S.W.: Inhibition of tumor cell growth by *RTP/rit42* and its responsiveness to p53 and DNA damage. Cancer Research 58:1-6, 1998.
498. Marmorstein, L.Y., Ouchi, T., and Aaronson, S.A.: The BRCA2 gene product functionally interacts with p53 and RAD51. Proc. Natl. Acad. Sci. USA 95:13869-13874, 1998.
499. Levin, A.C., Liu, X-H., Greenberg, P.D., Eliashili, M., Schiff, J.D., Aaronson, S.A., Holland, J.F., and Kirschenbaum, A.: Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 139(11):4672-4678.
500. Aaronson, S.A.: Robert Huebner Obituary. Cancer Research 58, 1998.

- 501 Fang, L., Igarashi, M., Leung, J., Sugrue, M.M., Lee, S.W., and Aaronson, S.A.: p21^{Waf1/Cip1/Sdi1} induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene 18:2789-2797, 1999.
- 502 Bafico, A., Gazit, A., Pramila, T., Finch, P.W., Yaniv, A., and Aaronson, S.A.: Interaction of FRP with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signalling. J Biol Chem Vol. 274, 16180-16187, 1999.
- 503 Fedi, P., and Aaronson, S.A.: Signal transduction through tyrosine kinase growth factor receptors. In "Signal Transduction, Cell Cycle and their Inhibitors" Edited by Gutkind et al., Humana Press, 1999
- 504 Reimer, C.L., Borrás, A.M., Kurdistani, S.K., Garreau, J.R., Chung, M., Aaronson, S.A., and Lee, S.W.: Altered regulation of cyclin G in human breast cancer and its specific localization at replication foci in response to DNA damage in p53^{+/+} cells. J Biol Chem Vol 274, 1999.
- 505 Fedi, P., Bafico, A., Soria, A.N., Burgess, W.H., Miki, T., Kraus, M.H., and Aaronson, S.A.: Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. Journal of Biological Chemistry, Vol 274, 19465-19471, 1999.

506. Gazit, A., Yaniv, A., Bafico, A., Pramila, T., Igarashi, M., Kitajewsky, J., and Aaronson, S.A.: Human frizzled 1 interacts with transforming Wnts to transduce a TCF dependent transcriptional response. Oncogene (In press)
507. Fang, L. Lee, S.W., and Aaronson, S.A., Comparative analysis of p73 and p53 regulation and effector functions. J. Cell Biol. 147:824-830, 1999.
508. Blaho, J.A., Aaronson, S.A.: Conviction of a human tumor virus: Guilt by association? Proc. Natl. Acad. Sci. USA 96:7619-7621, 1999.
509. Lee, S.W., Reimer, C., Fang, L., Iruela-Arispe, M.L., and Aaronson, S. A.: Overexpression of Kinase-Associated Phosphatase (KAP) in Breast and Prostate Expression. Mol. Cel. Biol. 20:1723-1732, 2000.
510. Hazan R, Phillips, Qia, Norton, L, Ossowski, L., Aaronson S. A.: Exogenous expression of N-cadherin in Breast Cancer cells induces cell migration, invasion and metastasis. J. Cell Biol. Vol 148, 779-790, 2000
511. Lee, S.W., Fang, L., Igarashi, M., Ouchi, T., Lu, K.P., and Aaronson, S.A.: Sustained activation of the MAP kinase cascade by the tumor suppressor p53. PNAS, 2000 (in press)
512. Kimmelman, A., Bafico, A., and Aaronson, S.A.: Oncogenes and Signal Transduction: Molecular Basis of Cancer, 2000 (in press),
513. Fedi, P., Kimmelman, A., and Aaronson, S.: Growth Factor Signal Transduction in Cancer, Cancer Medicine 5th Ed, 2000 (published)
514. Ouchi, T., Lee, S.W., Aaronson, S.A., and Horvath, C.: Collaboration of STAT1 and BRCA1 in Differential Regulation of IFN γ Target Genes, PNAS, Vol 97, 5208-5213, 2000.
515. Ariziti, P., Fang, L., Park, I., Yin, Y., Solomon, E., Ouchi, T., Aaronson, S., Lee, S.W., Tumor Suppressor p53 Is Required to Modulate BRCA1 Expression, Molecular and Cellular Biology, 2000